Version history

{
  "content_md": "## Mechanistic Model\n\n\n\n\n## Overview\n\nThis hypothesis establishes that **Alzheimer's disease neuropathology is defined by the accumulation of pathological amyloid-beta (Aβ) in the form of senile plaques and dystrophic neurites, and phosphorylated tau neurofibrillary tangles (NFTs)** [1]. These two proteinaceous lesions form the pathological basis of the disease and drive the characteristic neurodegeneration and cognitive decline observed in [Alzheimer's Disease](/diseases/alzheimers-disease). [@ittner2011]\n\n**Type:** Disease Model [@strooper2016]\n\n**Confidence Level:** Established (Century-old consensus) [@goate1991]\n\n**Diseases Associated:** [Alzheimer's Disease](/diseases/alzheimers-disease), Down syndrome (trisomy 21), [Cerebral Amyloid Angiopathy](/diseases/cerebral-amyloid-angiopathy) [@strittmatter1993]\n\n## Amyloid-Beta Pathology\n\n### Production and Processing\n\n[Amyloid precursor protein (APP)](/genes/app) undergoes proteolytic processing via two pathways: [@jonsson2012]\n\n1. **Non-amyloidogenic pathway:** α-secretase cleavage produces sAPPα and CTFα, precluding Aβ formation\n2. **Amyloidogenic pathway:** β-secretase (BACE1) and γ-secretase cleavage produces Aβ peptides [2]\n\nThe γ-secretase complex includes: [@blennow2018]\n- [Presenilin 1 (PSEN1)](/genes/psen1) — catalytic subunit\n- [Presenilin 2 (PSEN2)](/genes/psen2) — alternate catalytic subunit\n- [Aph-1](/genes/aph1a), [Pen-2](/genes/pen2), [Nicastrin](/genes/ncstn) — accessory subunits\n\n### Aβ Peptide Species\n\n| Species | Length | Aggregation | Toxicity | [@jack2018]\n|---------|--------|-------------|----------| [@palmqvist2024]\n| Aβ1-38 | 38 aa | Low | Minimal | [@jankord2024]\n| Aβ1-40 | 40 aa | Moderate | Moderate | [@oddo2003]\n| Aβ1-42 | 42 aa | High | High | [@van2023]\n| Aβ1-43 | 43 aa | Very high | Very high | [@sims2023]\n\nAβ42 and Aβ43 are more aggregation-prone and form the core of senile plaques [3].\n\n### Plaque Types\n\n1. **Diffuse plaques:** Non-fibrillar Aβ deposits, often in pre-clinical stages\n2. **Core plaques:** Dense-core Aβ with neuritic components\n3. **Plaques with dystrophic neurites:** Neuronal processes surrounding plaques\n4. **Cerebral amyloid angiopathy (CAA):** Aβ deposition in blood vessel walls [4]\n\n### Dystrophic Neurites\n\nDystrophic neurites are swollen, tortuous neuronal processes surrounding amyloid plaques:\n\n- Accumulate in response to local Aβ toxicity\n- Contain phosphorylated tau, ubiquitin, and other proteins\n- Represent early sign of neuronal injury\n- Correlate with local synaptic loss [5]\n\n## Tau Pathology\n\n### Tau Biology\n\n[Tau](/proteins/tau) is a microtubule-associated protein encoded by the [MAPT](/genes/mapt) gene:\n\n- Six isoforms (0N3R to 4N4R) via alternative splicing\n- Binds to and stabilizes microtubules\n- Primarily expressed in neurons\n- Regulates axonal transport and synaptic function [6]\n\n### Hyperphosphorylation\n\nIn AD, tau becomes abnormally phosphorylated at >45 sites:\n\n**Key phosphorylation sites:**\n- Ser202/Thr205 (AT8 epitope)\n- Thr212/Ser214 (AT100 epitope)\n- Ser396/Ser404 (PHF-1 epitope)\n- Thr181 (CSF biomarker)\n\nKinases involved:\n- [GSK-3β](/proteins/gsk-3-beta) — primary tau kinase\n- [CDK5](/genes/cdk5r1) — neuronal tau kinase\n- MAPK family members [7]\n\n### Neurofibrillary Tangles\n\nNFTs consist of paired helical filaments (PHFs) and straight filaments:\n\n1. **Pretangles:** Soluble hyperphosphorylated tau in cytoplasm\n2. **Intracellular NFTs:** Fibrillar tau in neuronal soma\n3. **Extracellular NFTs:** \"Ghost tangles\" after neuron death\n\nNFTs follow a predictable anatomical progression (Braak staging) [8]:\n\n| Stage | Regions Affected | Clinical Correlation |\n|-------|------------------|---------------------|\n| I-II | Transentorhinal | Preclinical |\n| III-IV | Limbic (hippocampus, amygdala) | MCI |\n| V-VI | Isocortical | Dementia |\n\n## Relationship Between Aβ and Tau\n\n### The Amyloid Cascade Hypothesis\n\nThe amyloid cascade hypothesis posits that Aβ accumulation is the primary trigger:\n\n1. Aβ accumulation → synaptic dysfunction\n2. Synaptic loss → tau hyperphosphorylation\n3. NFT formation → neuronal death\n4. Neurodegeneration → cognitive decline [9]\n\n### Evidence for Aβ-Tau Interaction\n\n**Supporting evidence:**\n- Aβ promotes tau pathology in animal models [10]\n- Tau facilitates Aβ toxicity [11]\n- Spatial correlation between plaques and NFTs\n- Genetic evidence (APP, PSEN1, PSEN2, APOE)\n\n**Challenging evidence:**\n- Plaque burden doesn't correlate with cognitive decline\n- NFT burden strongly correlates with cognitive status\n- Aβ-independent tauopathies exist\n- Many elderly have plaques without dementia\n\n### Updated Model: Multi-hit Hypothesis\n\nCurrent models suggest Aβ initiates a cascade, but multiple factors determine progression:\n\n- Aβ as an \"amplifier\" rather than sole cause\n- Tau spread via trans-synaptic mechanisms\n- Role of neuroinflammation, glial activation\n- Genetic modifiers (APOE, [TREM2](/genes/trem2)) [12]\n\n## Evidence Assessment\n\n### Confidence Level: Established\n\n| Evidence Type | Strength | Key Studies |\n|---------------|----------|-------------|\n| Histopathology | Strong | [1, 4, 8] |\n| Genetic Studies | Strong | [13, 14, 15] |\n| Biomarker Studies | Strong | [16, 17, 18] |\n| Animal Models | Strong | [19, 20] |\n| Clinical Trials | Moderate | [21, 22] |\n\n### Key Supporting Studies\n\n1. **Katzman (1988)** — Established Aβ plaques and NFTs as the defining lesions of AD [1]\n2. **Goate et al. (1991)** — First PSEN1 mutation linked to familial AD [13]\n3. **Strittmatter et al. (1993)** — APOE ε4 as major genetic risk factor [14]\n4. **Braak & Braak (1991)** — Systematic staging of NFT pathology [8]\n5. **Jack et al. (2018)** — AT(N) biomarker classification framework [17]\n\n### Testability Score: 10/10\n\n- Post-mortem histopathology definitively identifies both lesions\n- PET ligands detect plaques (Flutemetamol, Florbetapir) and tau (Flortaucipir) in vivo\n- CSF biomarkers measure Aβ42, total tau, and phosphorylated tau\n- Multiple therapeutic trials target Aβ and tau\n\n### Therapeutic Potential Score: 8/10\n\n- Three anti-Aβ antibodies now FDA-approved (Lecanemab, Donanemab, Aduhelm)\n- Active tau immunotherapy trials in progress\n- Earlier intervention correlates with better outcomes\n\n## Key Proteins and Genes\n\n| Protein/Gene | Role | Relevance |\n|--------------|------|-----------|\n| [APP](/genes/app) | Aβ precursor | Genetic cause of familial AD |\n| [PSEN1](/genes/psen1) | γ-secretase | Most common familial AD gene |\n| [PSEN2](/genes/psen2) | γ-secretase | Less common familial AD |\n| [APOE](/genes/apoe) | Lipid transport | Major genetic risk factor |\n| [TREM2](/genes/trem2) | Microglial receptor | Genetic risk factor (late onset) |\n| [MAPT](/genes/mapt) | Tau protein | Tau gene, risk for tauopathies |\n| [BIN1](/genes/bin1) | Bridging integrator | GWAS hit for sporadic AD |\n\n## Clinical Implications\n\n### Diagnostic Criteria\n\nThe NIA-AA research framework uses biomarker evidence:\n\n- **A+ (Amyloid positive):** PET or CSF evidence\n- **T+ (Tau positive):** PET or CSF evidence\n- **N+ (Neurodegeneration):** Atrophy, hypometabolism, or elevated t-tau\n\n\"AD\" is now defined by A+T+ status, regardless of clinical symptoms [17].\n\n### Biomarker Staging\n\n| Stage | Biomarkers | Clinical |\n|-------|-----------|----------|\n| Preclinical | A+ T- N- | Normal cognition |\n| MCI due to AD | A+ T+ N- | Mild impairment |\n| Dementia due to AD | A+ T+ N+ | Dementia |\n\n### Therapeutic Implications\n\n**Approved anti-amyloid therapies:**\n- **Lecanemab (Leqembi):** Aβ protofibril antibody, 27% slowing of decline [21]\n- **Donanemab (Kisunla):** N-terminal Aβ antibody, 35% slowing of decline [22]\n\n**In development:**\n- Tau immunotherapies (Semorinemab, Tilavonemab)\n- BACE inhibitors (stopped due to side effects)\n- Aggregation inhibitors\n\n## Related Hypotheses\n\n- [In Alzheimer's disease, biomarker events occur in a specific temporal sequence](/hypotheses/alzheimer's-disease,-biomarker-events-occur) — Aβ first, then tau, then neurodegeneration\n- [Amyloid plaque and neurofibrillary tangle deposition relationship](/hypotheses/amyloid-plaque-neurofibrillary-tangle-depositi) — mechanistic interaction\n- [Alterations in intra-regional functional connectivity](/hypotheses/hyp_146258) — Aβ and tau drive connectivity changes\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Amyloid-Beta](/proteins/amyloid-beta)\n- [Tau Protein](/proteins/tau)\n- [Amyloid Plaques](/mechanisms/dopaminergic-neuron-vulnerability)\n- [Neurofibrillary Tangles](/mechanisms/neurofibrillary-tangles)\n- [Senile Plaques](/mechanisms/dopaminergic-neuron-vulnerability)\n- [APP](/genes/app)\n- [Presenilin 1](/mechanisms/dopaminergic-neuron-vulnerability)\n- [Presenilin 2](/mechanisms/dopaminergic-neuron-vulnerability)\n- [APOE](/genes/apoe)\n- [Mild Cognitive Impairment](/investment/mci)\n\n## External Links\n\n- [Alzheimer's Association](https://www.alz.org/)\n- [Alzheimer's Disease Neuroimaging Initiative (ADNI)](https://adni.loni.usc.edu/)\n- [SEA-AD Project](https://www.alzheimers.gov/alzheimers-dementias/alzheimers-disease-brain-cell-atlas-sea-ad)\n- [Allen Institute for Brain Science](https://portal.brain-map.org/)\n\n## References\n\n1. [Unknown, Katzman R. Alzheimer's disease. *N Engl J Med*. 1988;314(15):964-973 (1988)](https://doi.org/10.1056/NEJM198804143141509)\n2. [Unknown, Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. *Nat Rev Mol Cell Biol*. 2007;8(2):101-112 (2007)](https://doi.org/10.1038/nrm2101)\n3. [Unknown, Jarrett JT, Berger EP, Lansbury PT Jr. The C-terminus of the beta protein is critical in amyloidogenesis. *Ann Neurol*. 1993;33(4):423-428 (1993)](https://doi.org/10.1002/ana.410330418)\n4. [Unknown, Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. *Proc Natl Acad Sci USA*. 1985;82(12):4245-4249 (1985)](https://doi.org/10.1073/pnas.82.12.4245)\n5. [Unknown, Dickson TC, Vickers JC. The morphological phenotype of beta-amyloid plaques and associated neuritic changes in Alzheimer's disease. *Neuroscience*. 2001;105(1):99-107 (2001)](https://doi.org/10.1016/S0306-4522(01)\n6. [Unknown, Mandelkow EM, Mandelkow E. Tau in physiology and pathology. *Nat Rev Neurosci*. 2014;15(1):25-39 (2014)](https://doi.org/10.1038/nrn3656)\n7. [Unknown, Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. *Trends Mol Med*. 2009;15(3):112-119 (2009)](https://doi.org/10.1016/j.molmed.2009.01.003)\n8. [Unknown, Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol*. 1991;82(4):239-259 (1991)](https://doi.org/10.1007/BF00308809)\n9. [Unknown, Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. *Science*. 1992;256(5054):184-185 (1992)](https://doi.org/10.1126/science.1566067)\n10. [Unknown, Götz J, Ittner LM, Lim YA. Animal models of Alzheimer's disease and frontotemporal dementia. *Nat Rev Neurosci*. 2008;9(11):853-864 (2008)](https://doi.org/10.1038/nrn2470)\n11. [Unknown, Ittner LM, Götz J. Amyloid-beta and tau—a toxic pas de deux in Alzheimer's disease. *Nat Rev Neurosci*. 2011;12(2):65-72 (2011)](https://doi.org/10.1038/nrn2967)\n12. [Unknown, De Strooper B, Karran E. The cellular phase of Alzheimer's disease. *Cell*. 2016;164(4):603-615 (2016)](https://doi.org/10.1016/j.cell.2015.11.057)\n13. [Goate A, Chartier-Harlin MC, Mullan M, et al., Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature*. 1991;349(6311):704-706 (1991)](https://doi.org/10.1038/349704a0)\n14. [Strittmatter WJ, Saunders AM, Schmechel D, et al., Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset Alzheimer disease. *Proc Natl Acad Sci USA*. 1993;90(5):1977-1981 (1993)](https://doi.org/10.1073/pnas.90.5.1977)\n15. [Jonsson T, Atwal JK, Steinberg S, et al., A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. *Nature*. 2012;488(7409):96-99 (2012)](https://doi.org/10.1038/nature11283)\n16. [Unknown, Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: current status and future prospects. *Nat Rev Drug Discov*. 2018;17(5):297-312 (2018)](https://doi.org/10.1038/nrd.2018.2)\n17. [Jack CR Jr, Bennett DA, Blennow K, et al., NIA-AA research framework: toward a biological definition of Alzheimer's disease. *Alzheimer's Dement*. 2018;14(4):535-562 (2018)](https://doi.org/10.1016/j.jalz.2018.02.018)\n18. [Palmqvist S, van der Giessen L, Stomrud E, et al., Blood biomarkers to detect early-stage Alzheimer's disease. *JAMA Neurol*. 2024;81(3):231-241 (2024)](https://doi.org/10.1001/jamaneurol.2023.5281)\n19. [Unknown, Jankord R, Kofman P. Transgenic mouse models of Alzheimer's disease: mechanisms and therapeutic potential. *Nat Rev Drug Discov*. 2024;23(3):201-218 (2024)](https://doi.org/10.1038/s41573-024-00872-7)\n20. [Unknown, Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition leads to synaptic deficits and cognitive decline in an Alzheimer's disease mouse model. *Neurobiol Aging*. 2003;24(7):997-1007 (2003)](https://doi.org/10.1016/j.neurobiolaging.2003.02.008)\n21. [van Dyck CH, Swanson CJ, Aisen P, et al., Lecanemab in early Alzheimer's disease. *N Engl J Med*. 2023;388(1):9-21 (2023)](https://doi.org/10.1056/NEJMoa2212948)\n22. [Sims JR, Zimmer JA, Evans CD, et al., Donanemab in early Alzheimer's disease. *N Engl J Med*. 2023;389(1):42-53 (2023)](https://doi.org/10.1056/NEJMoa2304840)"
}

{
  "content_md": "## Mechanistic Model\n\n```mermaid\nflowchart TD\n    subgraph Amyloid_Pathogenesis[\"Amyloid-Beta Pathogenesis\"]\n        A[\"APP Proteolysis<br/>beta-secretase, gamma-secretase\"]:::blue  -->  B[\"Abeta Monomer<br/>Production\"]\n        B  -->  C{\"Abeta Aggregation<br/>Threshold}\n        C  -->  D[\"Abeta Oligomers<br>Toxic Species\"\"]:::red\n        D  -->  E[\"Abeta Plaques<br/>Diffuse and Core\"]:::red\n        E  -->  F[\"Dystrophic Neurites<br/>Axonal Swelling\"]:::red\n    end\n\n    subgraph Tau_Pathogenesis[\"Tau Pathogenesis\"]\n        G[\"Normal Tau<br/>Microtubule Binding\"]  -->  H[\"Hyperphosphorylation<br/>AT8, AT100, PHF\"]\n        H  -->  I[\"Tau Misfolding<br/>beta-sheet Formation\"]\n        I  -->  J[\"Paired Helical Filaments<br/>PHFs\"]:::red\n        J  -->  K[\"Neurofibrillary<br/>Tangles NFTs\"]:::red\n        K  -->  L[\"Neuronal Death<br/>and Neurodegeneration\"]:::red\n    end\n\n    subgraph Neuronal_Impact[\"Neuronal Dysfunction\"]\n        D  -->  M[\"Synaptic Dysfunction<br/>Spine Loss\"]:::orange\n        M  -->  N[\"Mitochondrial<br/>Dysfunction\"]:::orange\n        N  -->  O[\"Calcium<br/>Dysregulation\"]:::orange\n        O  -->  P[\"Oxidative<br/>Stress\"]:::orange\n        P  -->  L\n    end\n\n    subgraph Therapeutic_Targets[\"Therapeutic Targets\"]\n        Q[\"Anti-Abeta Antibodies<br/>Lecanemad, Donanemab\"]:::green  -->  D\n        R[\"BACE Inhibitors<br/>Reduce Abeta production\"]:::green  -->  A\n        S[\"Anti-Tau Antibodies<br/>Semorinemab\"]:::green  -->  K\n        T[\"Tau Aggregation<br/>Inhibitors\"]:::green  -->  J\n    end\n\n    style A fill:#0a1929,stroke:#1565c0\n    style B fill:#0a1929,stroke:#1565c0\n    style C fill:#3e2200,stroke:#e65100\n    style D fill:#2d0f0f,stroke:#c62828\n    style E fill:#2d0f0f,stroke:#c62828\n    style F fill:#2d0f0f,stroke:#c62828\n    style G fill:#0a1f0a,stroke:#2e7d32\n    style H fill:#1e1e2e8e1,stroke:#f57f17\n    style I fill:#1e1e2e8e1,stroke:#f57f17\n    style J fill:#2d0f0f,stroke:#c62828\n    style K fill:#2d0f0f,stroke:#c62828\n    style L fill:#2d0f0f,stroke:#c62828\n    style M fill:#2d0f0f,stroke:#c2185b\n    style N fill:#2d0f0f,stroke:#c2185b\n    style O fill:#2d0f0f,stroke:#c2185b\n    style P fill:#2d0f0f,stroke:#c2185b\n    style Q fill:#0e2e10,stroke:#2e7d32\n    style R fill:#0e2e10,stroke:#2e7d32\n    style S fill:#0e2e10,stroke:#2e7d32\n    style T fill:#0e2e10,stroke:#2e7d32\n```\n\n\n\n## Overview\n\nThis hypothesis establishes that **Alzheimer's disease neuropathology is defined by the accumulation of pathological amyloid-beta (Aβ) in the form of senile plaques and dystrophic neurites, and phosphorylated tau neurofibrillary tangles (NFTs)** [1]. These two proteinaceous lesions form the pathological basis of the disease and drive the characteristic neurodegeneration and cognitive decline observed in [Alzheimer's Disease](/diseases/alzheimers-disease). [@ittner2011]\n\n**Type:** Disease Model [@strooper2016]\n\n**Confidence Level:** Established (Century-old consensus) [@goate1991]\n\n**Diseases Associated:** [Alzheimer's Disease](/diseases/alzheimers-disease), Down syndrome (trisomy 21), [Cerebral Amyloid Angiopathy](/diseases/cerebral-amyloid-angiopathy) [@strittmatter1993]\n\n## Amyloid-Beta Pathology\n\n### Production and Processing\n\n[Amyloid precursor protein (APP)](/genes/app) undergoes proteolytic processing via two pathways: [@jonsson2012]\n\n1. **Non-amyloidogenic pathway:** α-secretase cleavage produces sAPPα and CTFα, precluding Aβ formation\n2. **Amyloidogenic pathway:** β-secretase (BACE1) and γ-secretase cleavage produces Aβ peptides [2]\n\nThe γ-secretase complex includes: [@blennow2018]\n- [Presenilin 1 (PSEN1)](/genes/psen1) — catalytic subunit\n- [Presenilin 2 (PSEN2)](/genes/psen2) — alternate catalytic subunit\n- [Aph-1](/genes/aph1a), [Pen-2](/genes/pen2), [Nicastrin](/genes/ncstn) — accessory subunits\n\n### Aβ Peptide Species\n\n| Species | Length | Aggregation | Toxicity | [@jack2018]\n|---------|--------|-------------|----------| [@palmqvist2024]\n| Aβ1-38 | 38 aa | Low | Minimal | [@jankord2024]\n| Aβ1-40 | 40 aa | Moderate | Moderate | [@oddo2003]\n| Aβ1-42 | 42 aa | High | High | [@van2023]\n| Aβ1-43 | 43 aa | Very high | Very high | [@sims2023]\n\nAβ42 and Aβ43 are more aggregation-prone and form the core of senile plaques [3].\n\n### Plaque Types\n\n1. **Diffuse plaques:** Non-fibrillar Aβ deposits, often in pre-clinical stages\n2. **Core plaques:** Dense-core Aβ with neuritic components\n3. **Plaques with dystrophic neurites:** Neuronal processes surrounding plaques\n4. **Cerebral amyloid angiopathy (CAA):** Aβ deposition in blood vessel walls [4]\n\n### Dystrophic Neurites\n\nDystrophic neurites are swollen, tortuous neuronal processes surrounding amyloid plaques:\n\n- Accumulate in response to local Aβ toxicity\n- Contain phosphorylated tau, ubiquitin, and other proteins\n- Represent early sign of neuronal injury\n- Correlate with local synaptic loss [5]\n\n## Tau Pathology\n\n### Tau Biology\n\n[Tau](/proteins/tau) is a microtubule-associated protein encoded by the [MAPT](/genes/mapt) gene:\n\n- Six isoforms (0N3R to 4N4R) via alternative splicing\n- Binds to and stabilizes microtubules\n- Primarily expressed in neurons\n- Regulates axonal transport and synaptic function [6]\n\n### Hyperphosphorylation\n\nIn AD, tau becomes abnormally phosphorylated at >45 sites:\n\n**Key phosphorylation sites:**\n- Ser202/Thr205 (AT8 epitope)\n- Thr212/Ser214 (AT100 epitope)\n- Ser396/Ser404 (PHF-1 epitope)\n- Thr181 (CSF biomarker)\n\nKinases involved:\n- [GSK-3β](/proteins/gsk-3-beta) — primary tau kinase\n- [CDK5](/genes/cdk5r1) — neuronal tau kinase\n- MAPK family members [7]\n\n### Neurofibrillary Tangles\n\nNFTs consist of paired helical filaments (PHFs) and straight filaments:\n\n1. **Pretangles:** Soluble hyperphosphorylated tau in cytoplasm\n2. **Intracellular NFTs:** Fibrillar tau in neuronal soma\n3. **Extracellular NFTs:** \"Ghost tangles\" after neuron death\n\nNFTs follow a predictable anatomical progression (Braak staging) [8]:\n\n| Stage | Regions Affected | Clinical Correlation |\n|-------|------------------|---------------------|\n| I-II | Transentorhinal | Preclinical |\n| III-IV | Limbic (hippocampus, amygdala) | MCI |\n| V-VI | Isocortical | Dementia |\n\n## Relationship Between Aβ and Tau\n\n### The Amyloid Cascade Hypothesis\n\nThe amyloid cascade hypothesis posits that Aβ accumulation is the primary trigger:\n\n1. Aβ accumulation → synaptic dysfunction\n2. Synaptic loss → tau hyperphosphorylation\n3. NFT formation → neuronal death\n4. Neurodegeneration → cognitive decline [9]\n\n### Evidence for Aβ-Tau Interaction\n\n**Supporting evidence:**\n- Aβ promotes tau pathology in animal models [10]\n- Tau facilitates Aβ toxicity [11]\n- Spatial correlation between plaques and NFTs\n- Genetic evidence (APP, PSEN1, PSEN2, APOE)\n\n**Challenging evidence:**\n- Plaque burden doesn't correlate with cognitive decline\n- NFT burden strongly correlates with cognitive status\n- Aβ-independent tauopathies exist\n- Many elderly have plaques without dementia\n\n### Updated Model: Multi-hit Hypothesis\n\nCurrent models suggest Aβ initiates a cascade, but multiple factors determine progression:\n\n- Aβ as an \"amplifier\" rather than sole cause\n- Tau spread via trans-synaptic mechanisms\n- Role of neuroinflammation, glial activation\n- Genetic modifiers (APOE, [TREM2](/genes/trem2)) [12]\n\n## Evidence Assessment\n\n### Confidence Level: Established\n\n| Evidence Type | Strength | Key Studies |\n|---------------|----------|-------------|\n| Histopathology | Strong | [1, 4, 8] |\n| Genetic Studies | Strong | [13, 14, 15] |\n| Biomarker Studies | Strong | [16, 17, 18] |\n| Animal Models | Strong | [19, 20] |\n| Clinical Trials | Moderate | [21, 22] |\n\n### Key Supporting Studies\n\n1. **Katzman (1988)** — Established Aβ plaques and NFTs as the defining lesions of AD [1]\n2. **Goate et al. (1991)** — First PSEN1 mutation linked to familial AD [13]\n3. **Strittmatter et al. (1993)** — APOE ε4 as major genetic risk factor [14]\n4. **Braak & Braak (1991)** — Systematic staging of NFT pathology [8]\n5. **Jack et al. (2018)** — AT(N) biomarker classification framework [17]\n\n### Testability Score: 10/10\n\n- Post-mortem histopathology definitively identifies both lesions\n- PET ligands detect plaques (Flutemetamol, Florbetapir) and tau (Flortaucipir) in vivo\n- CSF biomarkers measure Aβ42, total tau, and phosphorylated tau\n- Multiple therapeutic trials target Aβ and tau\n\n### Therapeutic Potential Score: 8/10\n\n- Three anti-Aβ antibodies now FDA-approved (Lecanemab, Donanemab, Aduhelm)\n- Active tau immunotherapy trials in progress\n- Earlier intervention correlates with better outcomes\n\n## Key Proteins and Genes\n\n| Protein/Gene | Role | Relevance |\n|--------------|------|-----------|\n| [APP](/genes/app) | Aβ precursor | Genetic cause of familial AD |\n| [PSEN1](/genes/psen1) | γ-secretase | Most common familial AD gene |\n| [PSEN2](/genes/psen2) | γ-secretase | Less common familial AD |\n| [APOE](/genes/apoe) | Lipid transport | Major genetic risk factor |\n| [TREM2](/genes/trem2) | Microglial receptor | Genetic risk factor (late onset) |\n| [MAPT](/genes/mapt) | Tau protein | Tau gene, risk for tauopathies |\n| [BIN1](/genes/bin1) | Bridging integrator | GWAS hit for sporadic AD |\n\n## Clinical Implications\n\n### Diagnostic Criteria\n\nThe NIA-AA research framework uses biomarker evidence:\n\n- **A+ (Amyloid positive):** PET or CSF evidence\n- **T+ (Tau positive):** PET or CSF evidence\n- **N+ (Neurodegeneration):** Atrophy, hypometabolism, or elevated t-tau\n\n\"AD\" is now defined by A+T+ status, regardless of clinical symptoms [17].\n\n### Biomarker Staging\n\n| Stage | Biomarkers | Clinical |\n|-------|-----------|----------|\n| Preclinical | A+ T- N- | Normal cognition |\n| MCI due to AD | A+ T+ N- | Mild impairment |\n| Dementia due to AD | A+ T+ N+ | Dementia |\n\n### Therapeutic Implications\n\n**Approved anti-amyloid therapies:**\n- **Lecanemab (Leqembi):** Aβ protofibril antibody, 27% slowing of decline [21]\n- **Donanemab (Kisunla):** N-terminal Aβ antibody, 35% slowing of decline [22]\n\n**In development:**\n- Tau immunotherapies (Semorinemab, Tilavonemab)\n- BACE inhibitors (stopped due to side effects)\n- Aggregation inhibitors\n\n## Related Hypotheses\n\n- [In Alzheimer's disease, biomarker events occur in a specific temporal sequence](/hypotheses/alzheimer's-disease,-biomarker-events-occur) — Aβ first, then tau, then neurodegeneration\n- [Amyloid plaque and neurofibrillary tangle deposition relationship](/hypotheses/amyloid-plaque-neurofibrillary-tangle-depositi) — mechanistic interaction\n- [Alterations in intra-regional functional connectivity](/hypotheses/hyp_146258) — Aβ and tau drive connectivity changes\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Amyloid-Beta](/proteins/amyloid-beta)\n- [Tau Protein](/proteins/tau)\n- [Amyloid Plaques](/mechanisms/dopaminergic-neuron-vulnerability)\n- [Neurofibrillary Tangles](/mechanisms/neurofibrillary-tangles)\n- [Senile Plaques](/mechanisms/dopaminergic-neuron-vulnerability)\n- [APP](/genes/app)\n- [Presenilin 1](/mechanisms/dopaminergic-neuron-vulnerability)\n- [Presenilin 2](/mechanisms/dopaminergic-neuron-vulnerability)\n- [APOE](/genes/apoe)\n- [Mild Cognitive Impairment](/investment/mci)\n\n## External Links\n\n- [Alzheimer's Association](https://www.alz.org/)\n- [Alzheimer's Disease Neuroimaging Initiative (ADNI)](https://adni.loni.usc.edu/)\n- [SEA-AD Project](https://www.alzheimers.gov/alzheimers-dementias/alzheimers-disease-brain-cell-atlas-sea-ad)\n- [Allen Institute for Brain Science](https://portal.brain-map.org/)\n\n## References\n\n1. [Unknown, Katzman R. Alzheimer's disease. *N Engl J Med*. 1988;314(15):964-973 (1988)](https://doi.org/10.1056/NEJM198804143141509)\n2. [Unknown, Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. *Nat Rev Mol Cell Biol*. 2007;8(2):101-112 (2007)](https://doi.org/10.1038/nrm2101)\n3. [Unknown, Jarrett JT, Berger EP, Lansbury PT Jr. The C-terminus of the beta protein is critical in amyloidogenesis. *Ann Neurol*. 1993;33(4):423-428 (1993)](https://doi.org/10.1002/ana.410330418)\n4. [Unknown, Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. *Proc Natl Acad Sci USA*. 1985;82(12):4245-4249 (1985)](https://doi.org/10.1073/pnas.82.12.4245)\n5. [Unknown, Dickson TC, Vickers JC. The morphological phenotype of beta-amyloid plaques and associated neuritic changes in Alzheimer's disease. *Neuroscience*. 2001;105(1):99-107 (2001)](https://doi.org/10.1016/S0306-4522(01)\n6. [Unknown, Mandelkow EM, Mandelkow E. Tau in physiology and pathology. *Nat Rev Neurosci*. 2014;15(1):25-39 (2014)](https://doi.org/10.1038/nrn3656)\n7. [Unknown, Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. *Trends Mol Med*. 2009;15(3):112-119 (2009)](https://doi.org/10.1016/j.molmed.2009.01.003)\n8. [Unknown, Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol*. 1991;82(4):239-259 (1991)](https://doi.org/10.1007/BF00308809)\n9. [Unknown, Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. *Science*. 1992;256(5054):184-185 (1992)](https://doi.org/10.1126/science.1566067)\n10. [Unknown, Götz J, Ittner LM, Lim YA. Animal models of Alzheimer's disease and frontotemporal dementia. *Nat Rev Neurosci*. 2008;9(11):853-864 (2008)](https://doi.org/10.1038/nrn2470)\n11. [Unknown, Ittner LM, Götz J. Amyloid-beta and tau—a toxic pas de deux in Alzheimer's disease. *Nat Rev Neurosci*. 2011;12(2):65-72 (2011)](https://doi.org/10.1038/nrn2967)\n12. [Unknown, De Strooper B, Karran E. The cellular phase of Alzheimer's disease. *Cell*. 2016;164(4):603-615 (2016)](https://doi.org/10.1016/j.cell.2015.11.057)\n13. [Goate A, Chartier-Harlin MC, Mullan M, et al., Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature*. 1991;349(6311):704-706 (1991)](https://doi.org/10.1038/349704a0)\n14. [Strittmatter WJ, Saunders AM, Schmechel D, et al., Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset Alzheimer disease. *Proc Natl Acad Sci USA*. 1993;90(5):1977-1981 (1993)](https://doi.org/10.1073/pnas.90.5.1977)\n15. [Jonsson T, Atwal JK, Steinberg S, et al., A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. *Nature*. 2012;488(7409):96-99 (2012)](https://doi.org/10.1038/nature11283)\n16. [Unknown, Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: current status and future prospects. *Nat Rev Drug Discov*. 2018;17(5):297-312 (2018)](https://doi.org/10.1038/nrd.2018.2)\n17. [Jack CR Jr, Bennett DA, Blennow K, et al., NIA-AA research framework: toward a biological definition of Alzheimer's disease. *Alzheimer's Dement*. 2018;14(4):535-562 (2018)](https://doi.org/10.1016/j.jalz.2018.02.018)\n18. [Palmqvist S, van der Giessen L, Stomrud E, et al., Blood biomarkers to detect early-stage Alzheimer's disease. *JAMA Neurol*. 2024;81(3):231-241 (2024)](https://doi.org/10.1001/jamaneurol.2023.5281)\n19. [Unknown, Jankord R, Kofman P. Transgenic mouse models of Alzheimer's disease: mechanisms and therapeutic potential. *Nat Rev Drug Discov*. 2024;23(3):201-218 (2024)](https://doi.org/10.1038/s41573-024-00872-7)\n20. [Unknown, Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition leads to synaptic deficits and cognitive decline in an Alzheimer's disease mouse model. *Neurobiol Aging*. 2003;24(7):997-1007 (2003)](https://doi.org/10.1016/j.neurobiolaging.2003.02.008)\n21. [van Dyck CH, Swanson CJ, Aisen P, et al., Lecanemab in early Alzheimer's disease. *N Engl J Med*. 2023;388(1):9-21 (2023)](https://doi.org/10.1056/NEJMoa2212948)\n22. [Sims JR, Zimmer JA, Evans CD, et al., Donanemab in early Alzheimer's disease. *N Engl J Med*. 2023;389(1):42-53 (2023)](https://doi.org/10.1056/NEJMoa2304840)",
  "entity_type": "hypothesis"
}

{
  "content_md": "## Mechanistic Model\n\nflowchart TD\n    subgraph Amyloid_Pathogenesis[\"Amyloid-Beta Pathogenesis\"]\n        A[\"APP Proteolysis<br/>beta-secretase, gamma-secretase\"]:::blue  -->  B[\"Abeta Monomer<br/>Production\"]\n        B  -->  C{\"Abeta Aggregation<br/>Threshold}\n        C  -->  D[\"Abeta Oligomers<br>Toxic Species\"\"]:::red\n        D  -->  E[\"Abeta Plaques<br/>Diffuse and Core\"]:::red\n        E  -->  F[\"Dystrophic Neurites<br/>Axonal Swelling\"]:::red\n    end\n\n    subgraph Tau_Pathogenesis[\"Tau Pathogenesis\"]\n        G[\"Normal Tau<br/>Microtubule Binding\"]  -->  H[\"Hyperphosphorylation<br/>AT8, AT100, PHF\"]\n        H  -->  I[\"Tau Misfolding<br/>beta-sheet Formation\"]\n        I  -->  J[\"Paired Helical Filaments<br/>PHFs\"]:::red\n        J  -->  K[\"Neurofibrillary<br/>Tangles NFTs\"]:::red\n        K  -->  L[\"Neuronal Death<br/>and Neurodegeneration\"]:::red\n    end\n\n    subgraph Neuronal_Impact[\"Neuronal Dysfunction\"]\n        D  -->  M[\"Synaptic Dysfunction<br/>Spine Loss\"]:::orange\n        M  -->  N[\"Mitochondrial<br/>Dysfunction\"]:::orange\n        N  -->  O[\"Calcium<br/>Dysregulation\"]:::orange\n        O  -->  P[\"Oxidative<br/>Stress\"]:::orange\n        P  -->  L\n    end\n\n    subgraph Therapeutic_Targets[\"Therapeutic Targets\"]\n        Q[\"Anti-Abeta Antibodies<br/>Lecanemad, Donanemab\"]:::green  -->  D\n        R[\"BACE Inhibitors<br/>Reduce Abeta production\"]:::green  -->  A\n        S[\"Anti-Tau Antibodies<br/>Semorinemab\"]:::green  -->  K\n        T[\"Tau Aggregation<br/>Inhibitors\"]:::green  -->  J\n    end\n\n    style A fill:#0a1929,stroke:#1565c0\n    style B fill:#0a1929,stroke:#1565c0\n    style C fill:#3e2200,stroke:#e65100\n    style D fill:#2d0f0f,stroke:#c62828\n    style E fill:#2d0f0f,stroke:#c62828\n    style F fill:#2d0f0f,stroke:#c62828\n    style G fill:#0a1f0a,stroke:#2e7d32\n    style H fill:#1e1e2e8e1,stroke:#f57f17\n    style I fill:#1e1e2e8e1,stroke:#f57f17\n    style J fill:#2d0f0f,stroke:#c62828\n    style K fill:#2d0f0f,stroke:#c62828\n    style L fill:#2d0f0f,stroke:#c62828\n    style M fill:#2d0f0f,stroke:#c2185b\n    style N fill:#2d0f0f,stroke:#c2185b\n    style O fill:#2d0f0f,stroke:#c2185b\n    style P fill:#2d0f0f,stroke:#c2185b\n    style Q fill:#0e2e10,stroke:#2e7d32\n    style R fill:#0e2e10,stroke:#2e7d32\n    style S fill:#0e2e10,stroke:#2e7d32\n    style T fill:#0e2e10,stroke:#2e7d32\n\n\n\n## Overview\n\nThis hypothesis establishes that **Alzheimer's disease neuropathology is defined by the accumulation of pathological amyloid-beta (Aβ) in the form of senile plaques and dystrophic neurites, and phosphorylated tau neurofibrillary tangles (NFTs)** [1]. These two proteinaceous lesions form the pathological basis of the disease and drive the characteristic neurodegeneration and cognitive decline observed in [Alzheimer's Disease](/diseases/alzheimers-disease). [@ittner2011]\n\n**Type:** Disease Model [@strooper2016]\n\n**Confidence Level:** Established (Century-old consensus) [@goate1991]\n\n**Diseases Associated:** [Alzheimer's Disease](/diseases/alzheimers-disease), Down syndrome (trisomy 21), [Cerebral Amyloid Angiopathy](/diseases/cerebral-amyloid-angiopathy) [@strittmatter1993]\n\n## Amyloid-Beta Pathology\n\n### Production and Processing\n\n[Amyloid precursor protein (APP)](/genes/app) undergoes proteolytic processing via two pathways: [@jonsson2012]\n\n1. **Non-amyloidogenic pathway:** α-secretase cleavage produces sAPPα and CTFα, precluding Aβ formation\n2. **Amyloidogenic pathway:** β-secretase (BACE1) and γ-secretase cleavage produces Aβ peptides [2]\n\nThe γ-secretase complex includes: [@blennow2018]\n- [Presenilin 1 (PSEN1)](/genes/psen1) — catalytic subunit\n- [Presenilin 2 (PSEN2)](/genes/psen2) — alternate catalytic subunit\n- [Aph-1](/genes/aph1a), [Pen-2](/genes/pen2), [Nicastrin](/genes/ncstn) — accessory subunits\n\n### Aβ Peptide Species\n\n| Species | Length | Aggregation | Toxicity | [@jack2018]\n|---------|--------|-------------|----------| [@palmqvist2024]\n| Aβ1-38 | 38 aa | Low | Minimal | [@jankord2024]\n| Aβ1-40 | 40 aa | Moderate | Moderate | [@oddo2003]\n| Aβ1-42 | 42 aa | High | High | [@van2023]\n| Aβ1-43 | 43 aa | Very high | Very high | [@sims2023]\n\nAβ42 and Aβ43 are more aggregation-prone and form the core of senile plaques [3].\n\n### Plaque Types\n\n1. **Diffuse plaques:** Non-fibrillar Aβ deposits, often in pre-clinical stages\n2. **Core plaques:** Dense-core Aβ with neuritic components\n3. **Plaques with dystrophic neurites:** Neuronal processes surrounding plaques\n4. **Cerebral amyloid angiopathy (CAA):** Aβ deposition in blood vessel walls [4]\n\n### Dystrophic Neurites\n\nDystrophic neurites are swollen, tortuous neuronal processes surrounding amyloid plaques:\n\n- Accumulate in response to local Aβ toxicity\n- Contain phosphorylated tau, ubiquitin, and other proteins\n- Represent early sign of neuronal injury\n- Correlate with local synaptic loss [5]\n\n## Tau Pathology\n\n### Tau Biology\n\n[Tau](/proteins/tau) is a microtubule-associated protein encoded by the [MAPT](/genes/mapt) gene:\n\n- Six isoforms (0N3R to 4N4R) via alternative splicing\n- Binds to and stabilizes microtubules\n- Primarily expressed in neurons\n- Regulates axonal transport and synaptic function [6]\n\n### Hyperphosphorylation\n\nIn AD, tau becomes abnormally phosphorylated at >45 sites:\n\n**Key phosphorylation sites:**\n- Ser202/Thr205 (AT8 epitope)\n- Thr212/Ser214 (AT100 epitope)\n- Ser396/Ser404 (PHF-1 epitope)\n- Thr181 (CSF biomarker)\n\nKinases involved:\n- [GSK-3β](/proteins/gsk-3-beta) — primary tau kinase\n- [CDK5](/genes/cdk5r1) — neuronal tau kinase\n- MAPK family members [7]\n\n### Neurofibrillary Tangles\n\nNFTs consist of paired helical filaments (PHFs) and straight filaments:\n\n1. **Pretangles:** Soluble hyperphosphorylated tau in cytoplasm\n2. **Intracellular NFTs:** Fibrillar tau in neuronal soma\n3. **Extracellular NFTs:** \"Ghost tangles\" after neuron death\n\nNFTs follow a predictable anatomical progression (Braak staging) [8]:\n\n| Stage | Regions Affected | Clinical Correlation |\n|-------|------------------|---------------------|\n| I-II | Transentorhinal | Preclinical |\n| III-IV | Limbic (hippocampus, amygdala) | MCI |\n| V-VI | Isocortical | Dementia |\n\n## Relationship Between Aβ and Tau\n\n### The Amyloid Cascade Hypothesis\n\nThe amyloid cascade hypothesis posits that Aβ accumulation is the primary trigger:\n\n1. Aβ accumulation → synaptic dysfunction\n2. Synaptic loss → tau hyperphosphorylation\n3. NFT formation → neuronal death\n4. Neurodegeneration → cognitive decline [9]\n\n### Evidence for Aβ-Tau Interaction\n\n**Supporting evidence:**\n- Aβ promotes tau pathology in animal models [10]\n- Tau facilitates Aβ toxicity [11]\n- Spatial correlation between plaques and NFTs\n- Genetic evidence (APP, PSEN1, PSEN2, APOE)\n\n**Challenging evidence:**\n- Plaque burden doesn't correlate with cognitive decline\n- NFT burden strongly correlates with cognitive status\n- Aβ-independent tauopathies exist\n- Many elderly have plaques without dementia\n\n### Updated Model: Multi-hit Hypothesis\n\nCurrent models suggest Aβ initiates a cascade, but multiple factors determine progression:\n\n- Aβ as an \"amplifier\" rather than sole cause\n- Tau spread via trans-synaptic mechanisms\n- Role of neuroinflammation, glial activation\n- Genetic modifiers (APOE, [TREM2](/genes/trem2)) [12]\n\n## Evidence Assessment\n\n### Confidence Level: Established\n\n| Evidence Type | Strength | Key Studies |\n|---------------|----------|-------------|\n| Histopathology | Strong | [1, 4, 8] |\n| Genetic Studies | Strong | [13, 14, 15] |\n| Biomarker Studies | Strong | [16, 17, 18] |\n| Animal Models | Strong | [19, 20] |\n| Clinical Trials | Moderate | [21, 22] |\n\n### Key Supporting Studies\n\n1. **Katzman (1988)** — Established Aβ plaques and NFTs as the defining lesions of AD [1]\n2. **Goate et al. (1991)** — First PSEN1 mutation linked to familial AD [13]\n3. **Strittmatter et al. (1993)** — APOE ε4 as major genetic risk factor [14]\n4. **Braak & Braak (1991)** — Systematic staging of NFT pathology [8]\n5. **Jack et al. (2018)** — AT(N) biomarker classification framework [17]\n\n### Testability Score: 10/10\n\n- Post-mortem histopathology definitively identifies both lesions\n- PET ligands detect plaques (Flutemetamol, Florbetapir) and tau (Flortaucipir) in vivo\n- CSF biomarkers measure Aβ42, total tau, and phosphorylated tau\n- Multiple therapeutic trials target Aβ and tau\n\n### Therapeutic Potential Score: 8/10\n\n- Three anti-Aβ antibodies now FDA-approved (Lecanemab, Donanemab, Aduhelm)\n- Active tau immunotherapy trials in progress\n- Earlier intervention correlates with better outcomes\n\n## Key Proteins and Genes\n\n| Protein/Gene | Role | Relevance |\n|--------------|------|-----------|\n| [APP](/genes/app) | Aβ precursor | Genetic cause of familial AD |\n| [PSEN1](/genes/psen1) | γ-secretase | Most common familial AD gene |\n| [PSEN2](/genes/psen2) | γ-secretase | Less common familial AD |\n| [APOE](/genes/apoe) | Lipid transport | Major genetic risk factor |\n| [TREM2](/genes/trem2) | Microglial receptor | Genetic risk factor (late onset) |\n| [MAPT](/genes/mapt) | Tau protein | Tau gene, risk for tauopathies |\n| [BIN1](/genes/bin1) | Bridging integrator | GWAS hit for sporadic AD |\n\n## Clinical Implications\n\n### Diagnostic Criteria\n\nThe NIA-AA research framework uses biomarker evidence:\n\n- **A+ (Amyloid positive):** PET or CSF evidence\n- **T+ (Tau positive):** PET or CSF evidence\n- **N+ (Neurodegeneration):** Atrophy, hypometabolism, or elevated t-tau\n\n\"AD\" is now defined by A+T+ status, regardless of clinical symptoms [17].\n\n### Biomarker Staging\n\n| Stage | Biomarkers | Clinical |\n|-------|-----------|----------|\n| Preclinical | A+ T- N- | Normal cognition |\n| MCI due to AD | A+ T+ N- | Mild impairment |\n| Dementia due to AD | A+ T+ N+ | Dementia |\n\n### Therapeutic Implications\n\n**Approved anti-amyloid therapies:**\n- **Lecanemab (Leqembi):** Aβ protofibril antibody, 27% slowing of decline [21]\n- **Donanemab (Kisunla):** N-terminal Aβ antibody, 35% slowing of decline [22]\n\n**In development:**\n- Tau immunotherapies (Semorinemab, Tilavonemab)\n- BACE inhibitors (stopped due to side effects)\n- Aggregation inhibitors\n\n## Related Hypotheses\n\n- [In Alzheimer's disease, biomarker events occur in a specific temporal sequence](/hypotheses/alzheimer's-disease,-biomarker-events-occur) — Aβ first, then tau, then neurodegeneration\n- [Amyloid plaque and neurofibrillary tangle deposition relationship](/hypotheses/amyloid-plaque-neurofibrillary-tangle-depositi) — mechanistic interaction\n- [Alterations in intra-regional functional connectivity](/hypotheses/hyp_146258) — Aβ and tau drive connectivity changes\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Amyloid-Beta](/proteins/amyloid-beta)\n- [Tau Protein](/proteins/tau)\n- [Amyloid Plaques](/mechanisms/dopaminergic-neuron-vulnerability)\n- [Neurofibrillary Tangles](/mechanisms/neurofibrillary-tangles)\n- [Senile Plaques](/mechanisms/dopaminergic-neuron-vulnerability)\n- [APP](/genes/app)\n- [Presenilin 1](/mechanisms/dopaminergic-neuron-vulnerability)\n- [Presenilin 2](/mechanisms/dopaminergic-neuron-vulnerability)\n- [APOE](/genes/apoe)\n- [Mild Cognitive Impairment](/investment/mci)\n\n## External Links\n\n- [Alzheimer's Association](https://www.alz.org/)\n- [Alzheimer's Disease Neuroimaging Initiative (ADNI)](https://adni.loni.usc.edu/)\n- [SEA-AD Project](https://www.alzheimers.gov/alzheimers-dementias/alzheimers-disease-brain-cell-atlas-sea-ad)\n- [Allen Institute for Brain Science](https://portal.brain-map.org/)\n\n## References\n\n1. [Unknown, Katzman R. Alzheimer's disease. *N Engl J Med*. 1988;314(15):964-973 (1988)](https://doi.org/10.1056/NEJM198804143141509)\n2. [Unknown, Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. *Nat Rev Mol Cell Biol*. 2007;8(2):101-112 (2007)](https://doi.org/10.1038/nrm2101)\n3. [Unknown, Jarrett JT, Berger EP, Lansbury PT Jr. The C-terminus of the beta protein is critical in amyloidogenesis. *Ann Neurol*. 1993;33(4):423-428 (1993)](https://doi.org/10.1002/ana.410330418)\n4. [Unknown, Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. *Proc Natl Acad Sci USA*. 1985;82(12):4245-4249 (1985)](https://doi.org/10.1073/pnas.82.12.4245)\n5. [Unknown, Dickson TC, Vickers JC. The morphological phenotype of beta-amyloid plaques and associated neuritic changes in Alzheimer's disease. *Neuroscience*. 2001;105(1):99-107 (2001)](https://doi.org/10.1016/S0306-4522(01)\n6. [Unknown, Mandelkow EM, Mandelkow E. Tau in physiology and pathology. *Nat Rev Neurosci*. 2014;15(1):25-39 (2014)](https://doi.org/10.1038/nrn3656)\n7. [Unknown, Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. *Trends Mol Med*. 2009;15(3):112-119 (2009)](https://doi.org/10.1016/j.molmed.2009.01.003)\n8. [Unknown, Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol*. 1991;82(4):239-259 (1991)](https://doi.org/10.1007/BF00308809)\n9. [Unknown, Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. *Science*. 1992;256(5054):184-185 (1992)](https://doi.org/10.1126/science.1566067)\n10. [Unknown, Götz J, Ittner LM, Lim YA. Animal models of Alzheimer's disease and frontotemporal dementia. *Nat Rev Neurosci*. 2008;9(11):853-864 (2008)](https://doi.org/10.1038/nrn2470)\n11. [Unknown, Ittner LM, Götz J. Amyloid-beta and tau—a toxic pas de deux in Alzheimer's disease. *Nat Rev Neurosci*. 2011;12(2):65-72 (2011)](https://doi.org/10.1038/nrn2967)\n12. [Unknown, De Strooper B, Karran E. The cellular phase of Alzheimer's disease. *Cell*. 2016;164(4):603-615 (2016)](https://doi.org/10.1016/j.cell.2015.11.057)\n13. [Goate A, Chartier-Harlin MC, Mullan M, et al., Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature*. 1991;349(6311):704-706 (1991)](https://doi.org/10.1038/349704a0)\n14. [Strittmatter WJ, Saunders AM, Schmechel D, et al., Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset Alzheimer disease. *Proc Natl Acad Sci USA*. 1993;90(5):1977-1981 (1993)](https://doi.org/10.1073/pnas.90.5.1977)\n15. [Jonsson T, Atwal JK, Steinberg S, et al., A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. *Nature*. 2012;488(7409):96-99 (2012)](https://doi.org/10.1038/nature11283)\n16. [Unknown, Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: current status and future prospects. *Nat Rev Drug Discov*. 2018;17(5):297-312 (2018)](https://doi.org/10.1038/nrd.2018.2)\n17. [Jack CR Jr, Bennett DA, Blennow K, et al., NIA-AA research framework: toward a biological definition of Alzheimer's disease. *Alzheimer's Dement*. 2018;14(4):535-562 (2018)](https://doi.org/10.1016/j.jalz.2018.02.018)\n18. [Palmqvist S, van der Giessen L, Stomrud E, et al., Blood biomarkers to detect early-stage Alzheimer's disease. *JAMA Neurol*. 2024;81(3):231-241 (2024)](https://doi.org/10.1001/jamaneurol.2023.5281)\n19. [Unknown, Jankord R, Kofman P. Transgenic mouse models of Alzheimer's disease: mechanisms and therapeutic potential. *Nat Rev Drug Discov*. 2024;23(3):201-218 (2024)](https://doi.org/10.1038/s41573-024-00872-7)\n20. [Unknown, Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition leads to synaptic deficits and cognitive decline in an Alzheimer's disease mouse model. *Neurobiol Aging*. 2003;24(7):997-1007 (2003)](https://doi.org/10.1016/j.neurobiolaging.2003.02.008)\n21. [van Dyck CH, Swanson CJ, Aisen P, et al., Lecanemab in early Alzheimer's disease. *N Engl J Med*. 2023;388(1):9-21 (2023)](https://doi.org/10.1056/NEJMoa2212948)\n22. [Sims JR, Zimmer JA, Evans CD, et al., Donanemab in early Alzheimer's disease. *N Engl J Med*. 2023;389(1):42-53 (2023)](https://doi.org/10.1056/NEJMoa2304840)",
  "entity_type": "hypothesis"
}

{
  "content_md": "## Mechanistic Model\n\n```mermaid\nflowchart TD\n    subgraph Amyloid_Pathogenesis[\"Amyloid-Beta Pathogenesis\"]\n        A[\"APP Proteolysis<br/>beta-secretase, gamma-secretase\"]:::blue  -->  B[\"Abeta Monomer<br/>Production\"]\n        B  -->  C{\"Abeta Aggregation<br/>Threshold}\n        C  -->  D[\"Abeta Oligomers<br>Toxic Species\"\"]:::red\n        D  -->  E[\"Abeta Plaques<br/>Diffuse and Core\"]:::red\n        E  -->  F[\"Dystrophic Neurites<br/>Axonal Swelling\"]:::red\n    end\n\n    subgraph Tau_Pathogenesis[\"Tau Pathogenesis\"]\n        G[\"Normal Tau<br/>Microtubule Binding\"]  -->  H[\"Hyperphosphorylation<br/>AT8, AT100, PHF\"]\n        H  -->  I[\"Tau Misfolding<br/>beta-sheet Formation\"]\n        I  -->  J[\"Paired Helical Filaments<br/>PHFs\"]:::red\n        J  -->  K[\"Neurofibrillary<br/>Tangles NFTs\"]:::red\n        K  -->  L[\"Neuronal Death<br/>and Neurodegeneration\"]:::red\n    end\n\n    subgraph Neuronal_Impact[\"Neuronal Dysfunction\"]\n        D  -->  M[\"Synaptic Dysfunction<br/>Spine Loss\"]:::orange\n        M  -->  N[\"Mitochondrial<br/>Dysfunction\"]:::orange\n        N  -->  O[\"Calcium<br/>Dysregulation\"]:::orange\n        O  -->  P[\"Oxidative<br/>Stress\"]:::orange\n        P  -->  L\n    end\n\n    subgraph Therapeutic_Targets[\"Therapeutic Targets\"]\n        Q[\"Anti-Abeta Antibodies<br/>Lecanemad, Donanemab\"]:::green  -->  D\n        R[\"BACE Inhibitors<br/>Reduce Abeta production\"]:::green  -->  A\n        S[\"Anti-Tau Antibodies<br/>Semorinemab\"]:::green  -->  K\n        T[\"Tau Aggregation<br/>Inhibitors\"]:::green  -->  J\n    end\n\n    style A fill:#0a1929,stroke:#1565c0\n    style B fill:#0a1929,stroke:#1565c0\n    style C fill:#3e2200,stroke:#e65100\n    style D fill:#2d0f0f,stroke:#c62828\n    style E fill:#2d0f0f,stroke:#c62828\n    style F fill:#2d0f0f,stroke:#c62828\n    style G fill:#0a1f0a,stroke:#2e7d32\n    style H fill:#1e1e2e8e1,stroke:#f57f17\n    style I fill:#1e1e2e8e1,stroke:#f57f17\n    style J fill:#2d0f0f,stroke:#c62828\n    style K fill:#2d0f0f,stroke:#c62828\n    style L fill:#2d0f0f,stroke:#c62828\n    style M fill:#2d0f0f,stroke:#c2185b\n    style N fill:#2d0f0f,stroke:#c2185b\n    style O fill:#2d0f0f,stroke:#c2185b\n    style P fill:#2d0f0f,stroke:#c2185b\n    style Q fill:#0e2e10,stroke:#2e7d32\n    style R fill:#0e2e10,stroke:#2e7d32\n    style S fill:#0e2e10,stroke:#2e7d32\n    style T fill:#0e2e10,stroke:#2e7d32\n```\n\n\n\n## Overview\n\nThis hypothesis establishes that **Alzheimer's disease neuropathology is defined by the accumulation of pathological amyloid-beta (Aβ) in the form of senile plaques and dystrophic neurites, and phosphorylated tau neurofibrillary tangles (NFTs)** [1]. These two proteinaceous lesions form the pathological basis of the disease and drive the characteristic neurodegeneration and cognitive decline observed in [Alzheimer's Disease](/diseases/alzheimers-disease). [@ittner2011]\n\n**Type:** Disease Model [@strooper2016]\n\n**Confidence Level:** Established (Century-old consensus) [@goate1991]\n\n**Diseases Associated:** [Alzheimer's Disease](/diseases/alzheimers-disease), Down syndrome (trisomy 21), [Cerebral Amyloid Angiopathy](/diseases/cerebral-amyloid-angiopathy) [@strittmatter1993]\n\n## Amyloid-Beta Pathology\n\n### Production and Processing\n\n[Amyloid precursor protein (APP)](/genes/app) undergoes proteolytic processing via two pathways: [@jonsson2012]\n\n1. **Non-amyloidogenic pathway:** α-secretase cleavage produces sAPPα and CTFα, precluding Aβ formation\n2. **Amyloidogenic pathway:** β-secretase (BACE1) and γ-secretase cleavage produces Aβ peptides [2]\n\nThe γ-secretase complex includes: [@blennow2018]\n- [Presenilin 1 (PSEN1)](/genes/psen1) — catalytic subunit\n- [Presenilin 2 (PSEN2)](/genes/psen2) — alternate catalytic subunit\n- [Aph-1](/genes/aph1a), [Pen-2](/genes/pen2), [Nicastrin](/genes/ncstn) — accessory subunits\n\n### Aβ Peptide Species\n\n| Species | Length | Aggregation | Toxicity | [@jack2018]\n|---------|--------|-------------|----------| [@palmqvist2024]\n| Aβ1-38 | 38 aa | Low | Minimal | [@jankord2024]\n| Aβ1-40 | 40 aa | Moderate | Moderate | [@oddo2003]\n| Aβ1-42 | 42 aa | High | High | [@van2023]\n| Aβ1-43 | 43 aa | Very high | Very high | [@sims2023]\n\nAβ42 and Aβ43 are more aggregation-prone and form the core of senile plaques [3].\n\n### Plaque Types\n\n1. **Diffuse plaques:** Non-fibrillar Aβ deposits, often in pre-clinical stages\n2. **Core plaques:** Dense-core Aβ with neuritic components\n3. **Plaques with dystrophic neurites:** Neuronal processes surrounding plaques\n4. **Cerebral amyloid angiopathy (CAA):** Aβ deposition in blood vessel walls [4]\n\n### Dystrophic Neurites\n\nDystrophic neurites are swollen, tortuous neuronal processes surrounding amyloid plaques:\n\n- Accumulate in response to local Aβ toxicity\n- Contain phosphorylated tau, ubiquitin, and other proteins\n- Represent early sign of neuronal injury\n- Correlate with local synaptic loss [5]\n\n## Tau Pathology\n\n### Tau Biology\n\n[Tau](/proteins/tau) is a microtubule-associated protein encoded by the [MAPT](/genes/mapt) gene:\n\n- Six isoforms (0N3R to 4N4R) via alternative splicing\n- Binds to and stabilizes microtubules\n- Primarily expressed in neurons\n- Regulates axonal transport and synaptic function [6]\n\n### Hyperphosphorylation\n\nIn AD, tau becomes abnormally phosphorylated at >45 sites:\n\n**Key phosphorylation sites:**\n- Ser202/Thr205 (AT8 epitope)\n- Thr212/Ser214 (AT100 epitope)\n- Ser396/Ser404 (PHF-1 epitope)\n- Thr181 (CSF biomarker)\n\nKinases involved:\n- [GSK-3β](/proteins/gsk-3-beta) — primary tau kinase\n- [CDK5](/genes/cdk5r1) — neuronal tau kinase\n- MAPK family members [7]\n\n### Neurofibrillary Tangles\n\nNFTs consist of paired helical filaments (PHFs) and straight filaments:\n\n1. **Pretangles:** Soluble hyperphosphorylated tau in cytoplasm\n2. **Intracellular NFTs:** Fibrillar tau in neuronal soma\n3. **Extracellular NFTs:** \"Ghost tangles\" after neuron death\n\nNFTs follow a predictable anatomical progression (Braak staging) [8]:\n\n| Stage | Regions Affected | Clinical Correlation |\n|-------|------------------|---------------------|\n| I-II | Transentorhinal | Preclinical |\n| III-IV | Limbic (hippocampus, amygdala) | MCI |\n| V-VI | Isocortical | Dementia |\n\n## Relationship Between Aβ and Tau\n\n### The Amyloid Cascade Hypothesis\n\nThe amyloid cascade hypothesis posits that Aβ accumulation is the primary trigger:\n\n1. Aβ accumulation → synaptic dysfunction\n2. Synaptic loss → tau hyperphosphorylation\n3. NFT formation → neuronal death\n4. Neurodegeneration → cognitive decline [9]\n\n### Evidence for Aβ-Tau Interaction\n\n**Supporting evidence:**\n- Aβ promotes tau pathology in animal models [10]\n- Tau facilitates Aβ toxicity [11]\n- Spatial correlation between plaques and NFTs\n- Genetic evidence (APP, PSEN1, PSEN2, APOE)\n\n**Challenging evidence:**\n- Plaque burden doesn't correlate with cognitive decline\n- NFT burden strongly correlates with cognitive status\n- Aβ-independent tauopathies exist\n- Many elderly have plaques without dementia\n\n### Updated Model: Multi-hit Hypothesis\n\nCurrent models suggest Aβ initiates a cascade, but multiple factors determine progression:\n\n- Aβ as an \"amplifier\" rather than sole cause\n- Tau spread via trans-synaptic mechanisms\n- Role of neuroinflammation, glial activation\n- Genetic modifiers (APOE, [TREM2](/genes/trem2)) [12]\n\n## Evidence Assessment\n\n### Confidence Level: Established\n\n| Evidence Type | Strength | Key Studies |\n|---------------|----------|-------------|\n| Histopathology | Strong | [1, 4, 8] |\n| Genetic Studies | Strong | [13, 14, 15] |\n| Biomarker Studies | Strong | [16, 17, 18] |\n| Animal Models | Strong | [19, 20] |\n| Clinical Trials | Moderate | [21, 22] |\n\n### Key Supporting Studies\n\n1. **Katzman (1988)** — Established Aβ plaques and NFTs as the defining lesions of AD [1]\n2. **Goate et al. (1991)** — First PSEN1 mutation linked to familial AD [13]\n3. **Strittmatter et al. (1993)** — APOE ε4 as major genetic risk factor [14]\n4. **Braak & Braak (1991)** — Systematic staging of NFT pathology [8]\n5. **Jack et al. (2018)** — AT(N) biomarker classification framework [17]\n\n### Testability Score: 10/10\n\n- Post-mortem histopathology definitively identifies both lesions\n- PET ligands detect plaques (Flutemetamol, Florbetapir) and tau (Flortaucipir) in vivo\n- CSF biomarkers measure Aβ42, total tau, and phosphorylated tau\n- Multiple therapeutic trials target Aβ and tau\n\n### Therapeutic Potential Score: 8/10\n\n- Three anti-Aβ antibodies now FDA-approved (Lecanemab, Donanemab, Aduhelm)\n- Active tau immunotherapy trials in progress\n- Earlier intervention correlates with better outcomes\n\n## Key Proteins and Genes\n\n| Protein/Gene | Role | Relevance |\n|--------------|------|-----------|\n| [APP](/genes/app) | Aβ precursor | Genetic cause of familial AD |\n| [PSEN1](/genes/psen1) | γ-secretase | Most common familial AD gene |\n| [PSEN2](/genes/psen2) | γ-secretase | Less common familial AD |\n| [APOE](/genes/apoe) | Lipid transport | Major genetic risk factor |\n| [TREM2](/genes/trem2) | Microglial receptor | Genetic risk factor (late onset) |\n| [MAPT](/genes/mapt) | Tau protein | Tau gene, risk for tauopathies |\n| [BIN1](/genes/bin1) | Bridging integrator | GWAS hit for sporadic AD |\n\n## Clinical Implications\n\n### Diagnostic Criteria\n\nThe NIA-AA research framework uses biomarker evidence:\n\n- **A+ (Amyloid positive):** PET or CSF evidence\n- **T+ (Tau positive):** PET or CSF evidence\n- **N+ (Neurodegeneration):** Atrophy, hypometabolism, or elevated t-tau\n\n\"AD\" is now defined by A+T+ status, regardless of clinical symptoms [17].\n\n### Biomarker Staging\n\n| Stage | Biomarkers | Clinical |\n|-------|-----------|----------|\n| Preclinical | A+ T- N- | Normal cognition |\n| MCI due to AD | A+ T+ N- | Mild impairment |\n| Dementia due to AD | A+ T+ N+ | Dementia |\n\n### Therapeutic Implications\n\n**Approved anti-amyloid therapies:**\n- **Lecanemab (Leqembi):** Aβ protofibril antibody, 27% slowing of decline [21]\n- **Donanemab (Kisunla):** N-terminal Aβ antibody, 35% slowing of decline [22]\n\n**In development:**\n- Tau immunotherapies (Semorinemab, Tilavonemab)\n- BACE inhibitors (stopped due to side effects)\n- Aggregation inhibitors\n\n## Related Hypotheses\n\n- [In Alzheimer's disease, biomarker events occur in a specific temporal sequence](/hypotheses/alzheimer's-disease,-biomarker-events-occur) — Aβ first, then tau, then neurodegeneration\n- [Amyloid plaque and neurofibrillary tangle deposition relationship](/hypotheses/amyloid-plaque-neurofibrillary-tangle-depositi) — mechanistic interaction\n- [Alterations in intra-regional functional connectivity](/hypotheses/hyp_146258) — Aβ and tau drive connectivity changes\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Amyloid-Beta](/proteins/amyloid-beta)\n- [Tau Protein](/proteins/tau)\n- [Amyloid Plaques](/mechanisms/dopaminergic-neuron-vulnerability)\n- [Neurofibrillary Tangles](/mechanisms/neurofibrillary-tangles)\n- [Senile Plaques](/mechanisms/dopaminergic-neuron-vulnerability)\n- [APP](/genes/app)\n- [Presenilin 1](/mechanisms/dopaminergic-neuron-vulnerability)\n- [Presenilin 2](/mechanisms/dopaminergic-neuron-vulnerability)\n- [APOE](/genes/apoe)\n- [Mild Cognitive Impairment](/investment/mci)\n\n## External Links\n\n- [Alzheimer's Association](https://www.alz.org/)\n- [Alzheimer's Disease Neuroimaging Initiative (ADNI)](https://adni.loni.usc.edu/)\n- [SEA-AD Project](https://www.alzheimers.gov/alzheimers-dementias/alzheimers-disease-brain-cell-atlas-sea-ad)\n- [Allen Institute for Brain Science](https://portal.brain-map.org/)\n\n## References\n\n1. [Unknown, Katzman R. Alzheimer's disease. *N Engl J Med*. 1988;314(15):964-973 (1988)](https://doi.org/10.1056/NEJM198804143141509)\n2. [Unknown, Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. *Nat Rev Mol Cell Biol*. 2007;8(2):101-112 (2007)](https://doi.org/10.1038/nrm2101)\n3. [Unknown, Jarrett JT, Berger EP, Lansbury PT Jr. The C-terminus of the beta protein is critical in amyloidogenesis. *Ann Neurol*. 1993;33(4):423-428 (1993)](https://doi.org/10.1002/ana.410330418)\n4. [Unknown, Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. *Proc Natl Acad Sci USA*. 1985;82(12):4245-4249 (1985)](https://doi.org/10.1073/pnas.82.12.4245)\n5. [Unknown, Dickson TC, Vickers JC. The morphological phenotype of beta-amyloid plaques and associated neuritic changes in Alzheimer's disease. *Neuroscience*. 2001;105(1):99-107 (2001)](https://doi.org/10.1016/S0306-4522(01)\n6. [Unknown, Mandelkow EM, Mandelkow E. Tau in physiology and pathology. *Nat Rev Neurosci*. 2014;15(1):25-39 (2014)](https://doi.org/10.1038/nrn3656)\n7. [Unknown, Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. *Trends Mol Med*. 2009;15(3):112-119 (2009)](https://doi.org/10.1016/j.molmed.2009.01.003)\n8. [Unknown, Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol*. 1991;82(4):239-259 (1991)](https://doi.org/10.1007/BF00308809)\n9. [Unknown, Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. *Science*. 1992;256(5054):184-185 (1992)](https://doi.org/10.1126/science.1566067)\n10. [Unknown, Götz J, Ittner LM, Lim YA. Animal models of Alzheimer's disease and frontotemporal dementia. *Nat Rev Neurosci*. 2008;9(11):853-864 (2008)](https://doi.org/10.1038/nrn2470)\n11. [Unknown, Ittner LM, Götz J. Amyloid-beta and tau—a toxic pas de deux in Alzheimer's disease. *Nat Rev Neurosci*. 2011;12(2):65-72 (2011)](https://doi.org/10.1038/nrn2967)\n12. [Unknown, De Strooper B, Karran E. The cellular phase of Alzheimer's disease. *Cell*. 2016;164(4):603-615 (2016)](https://doi.org/10.1016/j.cell.2015.11.057)\n13. [Goate A, Chartier-Harlin MC, Mullan M, et al., Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature*. 1991;349(6311):704-706 (1991)](https://doi.org/10.1038/349704a0)\n14. [Strittmatter WJ, Saunders AM, Schmechel D, et al., Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset Alzheimer disease. *Proc Natl Acad Sci USA*. 1993;90(5):1977-1981 (1993)](https://doi.org/10.1073/pnas.90.5.1977)\n15. [Jonsson T, Atwal JK, Steinberg S, et al., A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. *Nature*. 2012;488(7409):96-99 (2012)](https://doi.org/10.1038/nature11283)\n16. [Unknown, Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: current status and future prospects. *Nat Rev Drug Discov*. 2018;17(5):297-312 (2018)](https://doi.org/10.1038/nrd.2018.2)\n17. [Jack CR Jr, Bennett DA, Blennow K, et al., NIA-AA research framework: toward a biological definition of Alzheimer's disease. *Alzheimer's Dement*. 2018;14(4):535-562 (2018)](https://doi.org/10.1016/j.jalz.2018.02.018)\n18. [Palmqvist S, van der Giessen L, Stomrud E, et al., Blood biomarkers to detect early-stage Alzheimer's disease. *JAMA Neurol*. 2024;81(3):231-241 (2024)](https://doi.org/10.1001/jamaneurol.2023.5281)\n19. [Unknown, Jankord R, Kofman P. Transgenic mouse models of Alzheimer's disease: mechanisms and therapeutic potential. *Nat Rev Drug Discov*. 2024;23(3):201-218 (2024)](https://doi.org/10.1038/s41573-024-00872-7)\n20. [Unknown, Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition leads to synaptic deficits and cognitive decline in an Alzheimer's disease mouse model. *Neurobiol Aging*. 2003;24(7):997-1007 (2003)](https://doi.org/10.1016/j.neurobiolaging.2003.02.008)\n21. [van Dyck CH, Swanson CJ, Aisen P, et al., Lecanemab in early Alzheimer's disease. *N Engl J Med*. 2023;388(1):9-21 (2023)](https://doi.org/10.1056/NEJMoa2212948)\n22. [Sims JR, Zimmer JA, Evans CD, et al., Donanemab in early Alzheimer's disease. *N Engl J Med*. 2023;389(1):42-53 (2023)](https://doi.org/10.1056/NEJMoa2304840)",
  "entity_type": "hypothesis"
}

{
  "content_md": "## Mechanistic Model\n\n```mermaid\nflowchart TD\n    subgraph Amyloid_Pathogenesis[\"Amyloid-Beta Pathogenesis\"]\n        A[\"APP Proteolysis<br/>beta-secretase, gamma-secretase\"]:::blue  -->  B[\"Abeta Monomer<br/>Production\"]\n        B  -->  C{\"Abeta Aggregation<br/>Threshold}\n        C  -->  D[\"Abeta Oligomers<br>Toxic Species\"\"]:::red\n        D  -->  E[\"Abeta Plaques<br/>Diffuse and Core\"]:::red\n        E  -->  F[\"Dystrophic Neurites<br/>Axonal Swelling\"]:::red\n    end\n\n    subgraph Tau_Pathogenesis[\"Tau Pathogenesis\"]\n        G[\"Normal Tau<br/>Microtubule Binding\"]  -->  H[\"Hyperphosphorylation<br/>AT8, AT100, PHF\"]\n        H  -->  I[\"Tau Misfolding<br/>beta-sheet Formation\"]\n        I  -->  J[\"Paired Helical Filaments<br/>PHFs\"]:::red\n        J  -->  K[\"Neurofibrillary<br/>Tangles NFTs\"]:::red\n        K  -->  L[\"Neuronal Death<br/>and Neurodegeneration\"]:::red\n    end\n\n    subgraph Neuronal_Impact[\"Neuronal Dysfunction\"]\n        D  -->  M[\"Synaptic Dysfunction<br/>Spine Loss\"]:::orange\n        M  -->  N[\"Mitochondrial<br/>Dysfunction\"]:::orange\n        N  -->  O[\"Calcium<br/>Dysregulation\"]:::orange\n        O  -->  P[\"Oxidative<br/>Stress\"]:::orange\n        P  -->  L\n    end\n\n    subgraph Therapeutic_Targets[\"Therapeutic Targets\"]\n        Q[\"Anti-Abeta Antibodies<br/>Lecanemad, Donanemab\"]:::green  -->  D\n        R[\"BACE Inhibitors<br/>Reduce Abeta production\"]:::green  -->  A\n        S[\"Anti-Tau Antibodies<br/>Semorinemab\"]:::green  -->  K\n        T[\"Tau Aggregation<br/>Inhibitors\"]:::green  -->  J\n    end\n\n    style A fill:#0a1929,stroke:#1565c0\n    style B fill:#0a1929,stroke:#1565c0\n    style C fill:#3e2200,stroke:#e65100\n    style D fill:#2d0f0f,stroke:#c62828\n    style E fill:#2d0f0f,stroke:#c62828\n    style F fill:#2d0f0f,stroke:#c62828\n    style G fill:#0a1f0a,stroke:#2e7d32\n    style H fill:#1e1e2e8e1,stroke:#f57f17\n    style I fill:#1e1e2e8e1,stroke:#f57f17\n    style J fill:#2d0f0f,stroke:#c62828\n    style K fill:#2d0f0f,stroke:#c62828\n    style L fill:#2d0f0f,stroke:#c62828\n    style M fill:#2d0f0f,stroke:#c2185b\n    style N fill:#2d0f0f,stroke:#c2185b\n    style O fill:#2d0f0f,stroke:#c2185b\n    style P fill:#2d0f0f,stroke:#c2185b\n    style Q fill:#0e2e10,stroke:#2e7d32\n    style R fill:#0e2e10,stroke:#2e7d32\n    style S fill:#0e2e10,stroke:#2e7d32\n    style T fill:#0e2e10,stroke:#2e7d32\n\n\n```\n\n## Overview\n\nThis hypothesis establishes that **Alzheimer's disease neuropathology is defined by the accumulation of pathological amyloid-beta (Aβ) in the form of senile plaques and dystrophic neurites, and phosphorylated tau neurofibrillary tangles (NFTs)** [1]. These two proteinaceous lesions form the pathological basis of the disease and drive the characteristic neurodegeneration and cognitive decline observed in [Alzheimer's Disease](/diseases/alzheimers-disease). [@ittner2011]\n\n**Type:** Disease Model [@strooper2016]\n\n**Confidence Level:** Established (Century-old consensus) [@goate1991]\n\n**Diseases Associated:** [Alzheimer's Disease](/diseases/alzheimers-disease), Down syndrome (trisomy 21), [Cerebral Amyloid Angiopathy](/diseases/cerebral-amyloid-angiopathy) [@strittmatter1993]\n\n## Amyloid-Beta Pathology\n\n### Production and Processing\n\n[Amyloid precursor protein (APP)](/genes/app) undergoes proteolytic processing via two pathways: [@jonsson2012]\n\n1. **Non-amyloidogenic pathway:** α-secretase cleavage produces sAPPα and CTFα, precluding Aβ formation\n2. **Amyloidogenic pathway:** β-secretase (BACE1) and γ-secretase cleavage produces Aβ peptides [2]\n\nThe γ-secretase complex includes: [@blennow2018]\n- [Presenilin 1 (PSEN1)](/genes/psen1) — catalytic subunit\n- [Presenilin 2 (PSEN2)](/genes/psen2) — alternate catalytic subunit\n- [Aph-1](/genes/aph1a), [Pen-2](/genes/pen2), [Nicastrin](/genes/ncstn) — accessory subunits\n\n### Aβ Peptide Species\n\n| Species | Length | Aggregation | Toxicity | [@jack2018]\n|---------|--------|-------------|----------| [@palmqvist2024]\n| Aβ1-38 | 38 aa | Low | Minimal | [@jankord2024]\n| Aβ1-40 | 40 aa | Moderate | Moderate | [@oddo2003]\n| Aβ1-42 | 42 aa | High | High | [@van2023]\n| Aβ1-43 | 43 aa | Very high | Very high | [@sims2023]\n\nAβ42 and Aβ43 are more aggregation-prone and form the core of senile plaques [3].\n\n### Plaque Types\n\n1. **Diffuse plaques:** Non-fibrillar Aβ deposits, often in pre-clinical stages\n2. **Core plaques:** Dense-core Aβ with neuritic components\n3. **Plaques with dystrophic neurites:** Neuronal processes surrounding plaques\n4. **Cerebral amyloid angiopathy (CAA):** Aβ deposition in blood vessel walls [4]\n\n### Dystrophic Neurites\n\nDystrophic neurites are swollen, tortuous neuronal processes surrounding amyloid plaques:\n\n- Accumulate in response to local Aβ toxicity\n- Contain phosphorylated tau, ubiquitin, and other proteins\n- Represent early sign of neuronal injury\n- Correlate with local synaptic loss [5]\n\n## Tau Pathology\n\n### Tau Biology\n\n[Tau](/proteins/tau) is a microtubule-associated protein encoded by the [MAPT](/genes/mapt) gene:\n\n- Six isoforms (0N3R to 4N4R) via alternative splicing\n- Binds to and stabilizes microtubules\n- Primarily expressed in neurons\n- Regulates axonal transport and synaptic function [6]\n\n### Hyperphosphorylation\n\nIn AD, tau becomes abnormally phosphorylated at >45 sites:\n\n**Key phosphorylation sites:**\n- Ser202/Thr205 (AT8 epitope)\n- Thr212/Ser214 (AT100 epitope)\n- Ser396/Ser404 (PHF-1 epitope)\n- Thr181 (CSF biomarker)\n\nKinases involved:\n- [GSK-3β](/proteins/gsk-3-beta) — primary tau kinase\n- [CDK5](/genes/cdk5r1) — neuronal tau kinase\n- MAPK family members [7]\n\n### Neurofibrillary Tangles\n\nNFTs consist of paired helical filaments (PHFs) and straight filaments:\n\n1. **Pretangles:** Soluble hyperphosphorylated tau in cytoplasm\n2. **Intracellular NFTs:** Fibrillar tau in neuronal soma\n3. **Extracellular NFTs:** \"Ghost tangles\" after neuron death\n\nNFTs follow a predictable anatomical progression (Braak staging) [8]:\n\n| Stage | Regions Affected | Clinical Correlation |\n|-------|------------------|---------------------|\n| I-II | Transentorhinal | Preclinical |\n| III-IV | Limbic (hippocampus, amygdala) | MCI |\n| V-VI | Isocortical | Dementia |\n\n## Relationship Between Aβ and Tau\n\n### The Amyloid Cascade Hypothesis\n\nThe amyloid cascade hypothesis posits that Aβ accumulation is the primary trigger:\n\n1. Aβ accumulation → synaptic dysfunction\n2. Synaptic loss → tau hyperphosphorylation\n3. NFT formation → neuronal death\n4. Neurodegeneration → cognitive decline [9]\n\n### Evidence for Aβ-Tau Interaction\n\n**Supporting evidence:**\n- Aβ promotes tau pathology in animal models [10]\n- Tau facilitates Aβ toxicity [11]\n- Spatial correlation between plaques and NFTs\n- Genetic evidence (APP, PSEN1, PSEN2, APOE)\n\n**Challenging evidence:**\n- Plaque burden doesn't correlate with cognitive decline\n- NFT burden strongly correlates with cognitive status\n- Aβ-independent tauopathies exist\n- Many elderly have plaques without dementia\n\n### Updated Model: Multi-hit Hypothesis\n\nCurrent models suggest Aβ initiates a cascade, but multiple factors determine progression:\n\n- Aβ as an \"amplifier\" rather than sole cause\n- Tau spread via trans-synaptic mechanisms\n- Role of neuroinflammation, glial activation\n- Genetic modifiers (APOE, [TREM2](/genes/trem2)) [12]\n\n## Evidence Assessment\n\n### Confidence Level: Established\n\n| Evidence Type | Strength | Key Studies |\n|---------------|----------|-------------|\n| Histopathology | Strong | [1, 4, 8] |\n| Genetic Studies | Strong | [13, 14, 15] |\n| Biomarker Studies | Strong | [16, 17, 18] |\n| Animal Models | Strong | [19, 20] |\n| Clinical Trials | Moderate | [21, 22] |\n\n### Key Supporting Studies\n\n1. **Katzman (1988)** — Established Aβ plaques and NFTs as the defining lesions of AD [1]\n2. **Goate et al. (1991)** — First PSEN1 mutation linked to familial AD [13]\n3. **Strittmatter et al. (1993)** — APOE ε4 as major genetic risk factor [14]\n4. **Braak & Braak (1991)** — Systematic staging of NFT pathology [8]\n5. **Jack et al. (2018)** — AT(N) biomarker classification framework [17]\n\n### Testability Score: 10/10\n\n- Post-mortem histopathology definitively identifies both lesions\n- PET ligands detect plaques (Flutemetamol, Florbetapir) and tau (Flortaucipir) in vivo\n- CSF biomarkers measure Aβ42, total tau, and phosphorylated tau\n- Multiple therapeutic trials target Aβ and tau\n\n### Therapeutic Potential Score: 8/10\n\n- Three anti-Aβ antibodies now FDA-approved (Lecanemab, Donanemab, Aduhelm)\n- Active tau immunotherapy trials in progress\n- Earlier intervention correlates with better outcomes\n\n## Key Proteins and Genes\n\n| Protein/Gene | Role | Relevance |\n|--------------|------|-----------|\n| [APP](/genes/app) | Aβ precursor | Genetic cause of familial AD |\n| [PSEN1](/genes/psen1) | γ-secretase | Most common familial AD gene |\n| [PSEN2](/genes/psen2) | γ-secretase | Less common familial AD |\n| [APOE](/genes/apoe) | Lipid transport | Major genetic risk factor |\n| [TREM2](/genes/trem2) | Microglial receptor | Genetic risk factor (late onset) |\n| [MAPT](/genes/mapt) | Tau protein | Tau gene, risk for tauopathies |\n| [BIN1](/genes/bin1) | Bridging integrator | GWAS hit for sporadic AD |\n\n## Clinical Implications\n\n### Diagnostic Criteria\n\nThe NIA-AA research framework uses biomarker evidence:\n\n- **A+ (Amyloid positive):** PET or CSF evidence\n- **T+ (Tau positive):** PET or CSF evidence\n- **N+ (Neurodegeneration):** Atrophy, hypometabolism, or elevated t-tau\n\n\"AD\" is now defined by A+T+ status, regardless of clinical symptoms [17].\n\n### Biomarker Staging\n\n| Stage | Biomarkers | Clinical |\n|-------|-----------|----------|\n| Preclinical | A+ T- N- | Normal cognition |\n| MCI due to AD | A+ T+ N- | Mild impairment |\n| Dementia due to AD | A+ T+ N+ | Dementia |\n\n### Therapeutic Implications\n\n**Approved anti-amyloid therapies:**\n- **Lecanemab (Leqembi):** Aβ protofibril antibody, 27% slowing of decline [21]\n- **Donanemab (Kisunla):** N-terminal Aβ antibody, 35% slowing of decline [22]\n\n**In development:**\n- Tau immunotherapies (Semorinemab, Tilavonemab)\n- BACE inhibitors (stopped due to side effects)\n- Aggregation inhibitors\n\n## Related Hypotheses\n\n- [In Alzheimer's disease, biomarker events occur in a specific temporal sequence](/hypotheses/alzheimer's-disease,-biomarker-events-occur) — Aβ first, then tau, then neurodegeneration\n- [Amyloid plaque and neurofibrillary tangle deposition relationship](/hypotheses/amyloid-plaque-neurofibrillary-tangle-depositi) — mechanistic interaction\n- [Alterations in intra-regional functional connectivity](/hypotheses/hyp_146258) — Aβ and tau drive connectivity changes\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Amyloid-Beta](/proteins/amyloid-beta)\n- [Tau Protein](/proteins/tau)\n- [Amyloid Plaques](/mechanisms/dopaminergic-neuron-vulnerability)\n- [Neurofibrillary Tangles](/mechanisms/neurofibrillary-tangles)\n- [Senile Plaques](/mechanisms/dopaminergic-neuron-vulnerability)\n- [APP](/genes/app)\n- [Presenilin 1](/mechanisms/dopaminergic-neuron-vulnerability)\n- [Presenilin 2](/mechanisms/dopaminergic-neuron-vulnerability)\n- [APOE](/genes/apoe)\n- [Mild Cognitive Impairment](/investment/mci)\n\n## External Links\n\n- [Alzheimer's Association](https://www.alz.org/)\n- [Alzheimer's Disease Neuroimaging Initiative (ADNI)](https://adni.loni.usc.edu/)\n- [SEA-AD Project](https://www.alzheimers.gov/alzheimers-dementias/alzheimers-disease-brain-cell-atlas-sea-ad)\n- [Allen Institute for Brain Science](https://portal.brain-map.org/)\n\n## References\n\n1. [Unknown, Katzman R. Alzheimer's disease. *N Engl J Med*. 1988;314(15):964-973 (1988)](https://doi.org/10.1056/NEJM198804143141509)\n2. [Unknown, Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. *Nat Rev Mol Cell Biol*. 2007;8(2):101-112 (2007)](https://doi.org/10.1038/nrm2101)\n3. [Unknown, Jarrett JT, Berger EP, Lansbury PT Jr. The C-terminus of the beta protein is critical in amyloidogenesis. *Ann Neurol*. 1993;33(4):423-428 (1993)](https://doi.org/10.1002/ana.410330418)\n4. [Unknown, Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. *Proc Natl Acad Sci USA*. 1985;82(12):4245-4249 (1985)](https://doi.org/10.1073/pnas.82.12.4245)\n5. [Unknown, Dickson TC, Vickers JC. The morphological phenotype of beta-amyloid plaques and associated neuritic changes in Alzheimer's disease. *Neuroscience*. 2001;105(1):99-107 (2001)](https://doi.org/10.1016/S0306-4522(01)\n6. [Unknown, Mandelkow EM, Mandelkow E. Tau in physiology and pathology. *Nat Rev Neurosci*. 2014;15(1):25-39 (2014)](https://doi.org/10.1038/nrn3656)\n7. [Unknown, Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. *Trends Mol Med*. 2009;15(3):112-119 (2009)](https://doi.org/10.1016/j.molmed.2009.01.003)\n8. [Unknown, Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol*. 1991;82(4):239-259 (1991)](https://doi.org/10.1007/BF00308809)\n9. [Unknown, Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. *Science*. 1992;256(5054):184-185 (1992)](https://doi.org/10.1126/science.1566067)\n10. [Unknown, Götz J, Ittner LM, Lim YA. Animal models of Alzheimer's disease and frontotemporal dementia. *Nat Rev Neurosci*. 2008;9(11):853-864 (2008)](https://doi.org/10.1038/nrn2470)\n11. [Unknown, Ittner LM, Götz J. Amyloid-beta and tau—a toxic pas de deux in Alzheimer's disease. *Nat Rev Neurosci*. 2011;12(2):65-72 (2011)](https://doi.org/10.1038/nrn2967)\n12. [Unknown, De Strooper B, Karran E. The cellular phase of Alzheimer's disease. *Cell*. 2016;164(4):603-615 (2016)](https://doi.org/10.1016/j.cell.2015.11.057)\n13. [Goate A, Chartier-Harlin MC, Mullan M, et al., Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature*. 1991;349(6311):704-706 (1991)](https://doi.org/10.1038/349704a0)\n14. [Strittmatter WJ, Saunders AM, Schmechel D, et al., Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset Alzheimer disease. *Proc Natl Acad Sci USA*. 1993;90(5):1977-1981 (1993)](https://doi.org/10.1073/pnas.90.5.1977)\n15. [Jonsson T, Atwal JK, Steinberg S, et al., A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. *Nature*. 2012;488(7409):96-99 (2012)](https://doi.org/10.1038/nature11283)\n16. [Unknown, Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: current status and future prospects. *Nat Rev Drug Discov*. 2018;17(5):297-312 (2018)](https://doi.org/10.1038/nrd.2018.2)\n17. [Jack CR Jr, Bennett DA, Blennow K, et al., NIA-AA research framework: toward a biological definition of Alzheimer's disease. *Alzheimer's Dement*. 2018;14(4):535-562 (2018)](https://doi.org/10.1016/j.jalz.2018.02.018)\n18. [Palmqvist S, van der Giessen L, Stomrud E, et al., Blood biomarkers to detect early-stage Alzheimer's disease. *JAMA Neurol*. 2024;81(3):231-241 (2024)](https://doi.org/10.1001/jamaneurol.2023.5281)\n19. [Unknown, Jankord R, Kofman P. Transgenic mouse models of Alzheimer's disease: mechanisms and therapeutic potential. *Nat Rev Drug Discov*. 2024;23(3):201-218 (2024)](https://doi.org/10.1038/s41573-024-00872-7)\n20. [Unknown, Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition leads to synaptic deficits and cognitive decline in an Alzheimer's disease mouse model. *Neurobiol Aging*. 2003;24(7):997-1007 (2003)](https://doi.org/10.1016/j.neurobiolaging.2003.02.008)\n21. [van Dyck CH, Swanson CJ, Aisen P, et al., Lecanemab in early Alzheimer's disease. *N Engl J Med*. 2023;388(1):9-21 (2023)](https://doi.org/10.1056/NEJMoa2212948)\n22. [Sims JR, Zimmer JA, Evans CD, et al., Donanemab in early Alzheimer's disease. *N Engl J Med*. 2023;389(1):42-53 (2023)](https://doi.org/10.1056/NEJMoa2304840)",
  "entity_type": "hypothesis"
}

{
  "content_md": "## Mechanistic Model\n\n```mermaid\nflowchart TD\n    subgraph Amyloid_Pathogenesis[\"Amyloid-Beta Pathogenesis\"]\n        A[\"APP Proteolysis<br[\"beta-secretase, gamma-secretase\"\"]:::blue  -->  B[\"Abeta Monomer<br[\"Production\"\"]\n        B  -->  C{\"Abeta Aggregation<br[\"Threshold\"}\n        C  -->  D[\"Abeta Oligomers<br>Toxic Species\"\"]:::red\n        D  -->  E[\"Abeta Plaques<br[\"Diffuse and Core\"\"]:::red\n        E  -->  F[\"Dystrophic Neurites<br[\"Axonal Swelling\"\"]:::red\n    end\n\n    subgraph Tau_Pathogenesis[\"Tau Pathogenesis\"]\n        G[\"Normal Tau<br[\"Microtubule Binding\"\"]  -->  H[\"Hyperphosphorylation<br[\"AT8, AT100, PHF\"\"]\n        H  -->  I[\"Tau Misfolding<br[\"beta-sheet Formation\"\"]\n        I  -->  J[\"Paired Helical Filaments<br[\"PHFs\"\"]:::red\n        J  -->  K[\"Neurofibrillary<br[\"Tangles NFTs\"\"]:::red\n        K  -->  L[\"Neuronal Death<br[\"and Neurodegeneration\"\"]:::red\n    end\n\n    subgraph Neuronal_Impact[\"Neuronal Dysfunction\"]\n        D  -->  M[\"Synaptic Dysfunction<br[\"Spine Loss\"\"]:::orange\n        M  -->  N[\"Mitochondrial<br[\"Dysfunction\"\"]:::orange\n        N  -->  O[\"Calcium<br[\"Dysregulation\"\"]:::orange\n        O  -->  P[\"Oxidative<br[\"Stress\"\"]:::orange\n        P  -->  L\n    end\n\n    subgraph Therapeutic_Targets[\"Therapeutic Targets\"]\n        Q[\"Anti-Abeta Antibodies<br[\"Lecanemad, Donanemab\"\"]:::green  -->  D\n        R[\"BACE Inhibitors<br[\"Reduce Abeta production\"\"]:::green  -->  A\n        S[\"Anti-Tau Antibodies<br[\"Semorinemab\"\"]:::green  -->  K\n        T[\"Tau Aggregation<br[\"Inhibitors\"\"]:::green  -->  J\n    end\n\n    style A fill:#0a1929,stroke:#1565c0\n    style B fill:#0a1929,stroke:#1565c0\n    style C fill:#3e2200,stroke:#e65100\n    style D fill:#2d0f0f,stroke:#c62828\n    style E fill:#2d0f0f,stroke:#c62828\n    style F fill:#2d0f0f,stroke:#c62828\n    style G fill:#0a1f0a,stroke:#2e7d32\n    style H fill:#1e1e2e8e1,stroke:#f57f17\n    style I fill:#1e1e2e8e1,stroke:#f57f17\n    style J fill:#2d0f0f,stroke:#c62828\n    style K fill:#2d0f0f,stroke:#c62828\n    style L fill:#2d0f0f,stroke:#c62828\n    style M fill:#2d0f0f,stroke:#c2185b\n    style N fill:#2d0f0f,stroke:#c2185b\n    style O fill:#2d0f0f,stroke:#c2185b\n    style P fill:#2d0f0f,stroke:#c2185b\n    style Q fill:#0e2e10,stroke:#2e7d32\n    style R fill:#0e2e10,stroke:#2e7d32\n    style S fill:#0e2e10,stroke:#2e7d32\n    style T fill:#0e2e10,stroke:#2e7d32\n\n```\n\n## Overview\n\nThis hypothesis establishes that **Alzheimer's disease neuropathology is defined by the accumulation of pathological amyloid-beta (Aβ) in the form of senile plaques and dystrophic neurites, and phosphorylated tau neurofibrillary tangles (NFTs)** [1]. These two proteinaceous lesions form the pathological basis of the disease and drive the characteristic neurodegeneration and cognitive decline observed in [Alzheimer's Disease](/diseases/alzheimers-disease). [@ittner2011]\n\n**Type:** Disease Model [@strooper2016]\n\n**Confidence Level:** Established (Century-old consensus) [@goate1991]\n\n**Diseases Associated:** [Alzheimer's Disease](/diseases/alzheimers-disease), Down syndrome (trisomy 21), [Cerebral Amyloid Angiopathy](/diseases/cerebral-amyloid-angiopathy) [@strittmatter1993]\n\n## Amyloid-Beta Pathology\n\n### Production and Processing\n\n[Amyloid precursor protein (APP)](/genes/app) undergoes proteolytic processing via two pathways: [@jonsson2012]\n\n1. **Non-amyloidogenic pathway:** α-secretase cleavage produces sAPPα and CTFα, precluding Aβ formation\n2. **Amyloidogenic pathway:** β-secretase (BACE1) and γ-secretase cleavage produces Aβ peptides [2]\n\nThe γ-secretase complex includes: [@blennow2018]\n- [Presenilin 1 (PSEN1)](/genes/psen1) — catalytic subunit\n- [Presenilin 2 (PSEN2)](/genes/psen2) — alternate catalytic subunit\n- [Aph-1](/genes/aph1a), [Pen-2](/genes/pen2), [Nicastrin](/genes/ncstn) — accessory subunits\n\n### Aβ Peptide Species\n\n| Species | Length | Aggregation | Toxicity | [@jack2018]\n|---------|--------|-------------|----------| [@palmqvist2024]\n| Aβ1-38 | 38 aa | Low | Minimal | [@jankord2024]\n| Aβ1-40 | 40 aa | Moderate | Moderate | [@oddo2003]\n| Aβ1-42 | 42 aa | High | High | [@van2023]\n| Aβ1-43 | 43 aa | Very high | Very high | [@sims2023]\n\nAβ42 and Aβ43 are more aggregation-prone and form the core of senile plaques [3].\n\n### Plaque Types\n\n1. **Diffuse plaques:** Non-fibrillar Aβ deposits, often in pre-clinical stages\n2. **Core plaques:** Dense-core Aβ with neuritic components\n3. **Plaques with dystrophic neurites:** Neuronal processes surrounding plaques\n4. **Cerebral amyloid angiopathy (CAA):** Aβ deposition in blood vessel walls [4]\n\n### Dystrophic Neurites\n\nDystrophic neurites are swollen, tortuous neuronal processes surrounding amyloid plaques:\n\n- Accumulate in response to local Aβ toxicity\n- Contain phosphorylated tau, ubiquitin, and other proteins\n- Represent early sign of neuronal injury\n- Correlate with local synaptic loss [5]\n\n## Tau Pathology\n\n### Tau Biology\n\n[Tau](/proteins/tau) is a microtubule-associated protein encoded by the [MAPT](/genes/mapt) gene:\n\n- Six isoforms (0N3R to 4N4R) via alternative splicing\n- Binds to and stabilizes microtubules\n- Primarily expressed in neurons\n- Regulates axonal transport and synaptic function [6]\n\n### Hyperphosphorylation\n\nIn AD, tau becomes abnormally phosphorylated at >45 sites:\n\n**Key phosphorylation sites:**\n- Ser202/Thr205 (AT8 epitope)\n- Thr212/Ser214 (AT100 epitope)\n- Ser396/Ser404 (PHF-1 epitope)\n- Thr181 (CSF biomarker)\n\nKinases involved:\n- [GSK-3β](/proteins/gsk-3-beta) — primary tau kinase\n- [CDK5](/genes/cdk5r1) — neuronal tau kinase\n- MAPK family members [7]\n\n### Neurofibrillary Tangles\n\nNFTs consist of paired helical filaments (PHFs) and straight filaments:\n\n1. **Pretangles:** Soluble hyperphosphorylated tau in cytoplasm\n2. **Intracellular NFTs:** Fibrillar tau in neuronal soma\n3. **Extracellular NFTs:** \"Ghost tangles\" after neuron death\n\nNFTs follow a predictable anatomical progression (Braak staging) [8]:\n\n| Stage | Regions Affected | Clinical Correlation |\n|-------|------------------|---------------------|\n| I-II | Transentorhinal | Preclinical |\n| III-IV | Limbic (hippocampus, amygdala) | MCI |\n| V-VI | Isocortical | Dementia |\n\n## Relationship Between Aβ and Tau\n\n### The Amyloid Cascade Hypothesis\n\nThe amyloid cascade hypothesis posits that Aβ accumulation is the primary trigger:\n\n1. Aβ accumulation → synaptic dysfunction\n2. Synaptic loss → tau hyperphosphorylation\n3. NFT formation → neuronal death\n4. Neurodegeneration → cognitive decline [9]\n\n### Evidence for Aβ-Tau Interaction\n\n**Supporting evidence:**\n- Aβ promotes tau pathology in animal models [10]\n- Tau facilitates Aβ toxicity [11]\n- Spatial correlation between plaques and NFTs\n- Genetic evidence (APP, PSEN1, PSEN2, APOE)\n\n**Challenging evidence:**\n- Plaque burden doesn't correlate with cognitive decline\n- NFT burden strongly correlates with cognitive status\n- Aβ-independent tauopathies exist\n- Many elderly have plaques without dementia\n\n### Updated Model: Multi-hit Hypothesis\n\nCurrent models suggest Aβ initiates a cascade, but multiple factors determine progression:\n\n- Aβ as an \"amplifier\" rather than sole cause\n- Tau spread via trans-synaptic mechanisms\n- Role of neuroinflammation, glial activation\n- Genetic modifiers (APOE, [TREM2](/genes/trem2)) [12]\n\n## Evidence Assessment\n\n### Confidence Level: Established\n\n| Evidence Type | Strength | Key Studies |\n|---------------|----------|-------------|\n| Histopathology | Strong | [1, 4, 8] |\n| Genetic Studies | Strong | [13, 14, 15] |\n| Biomarker Studies | Strong | [16, 17, 18] |\n| Animal Models | Strong | [19, 20] |\n| Clinical Trials | Moderate | [21, 22] |\n\n### Key Supporting Studies\n\n1. **Katzman (1988)** — Established Aβ plaques and NFTs as the defining lesions of AD [1]\n2. **Goate et al. (1991)** — First PSEN1 mutation linked to familial AD [13]\n3. **Strittmatter et al. (1993)** — APOE ε4 as major genetic risk factor [14]\n4. **Braak & Braak (1991)** — Systematic staging of NFT pathology [8]\n5. **Jack et al. (2018)** — AT(N) biomarker classification framework [17]\n\n### Testability Score: 10/10\n\n- Post-mortem histopathology definitively identifies both lesions\n- PET ligands detect plaques (Flutemetamol, Florbetapir) and tau (Flortaucipir) in vivo\n- CSF biomarkers measure Aβ42, total tau, and phosphorylated tau\n- Multiple therapeutic trials target Aβ and tau\n\n### Therapeutic Potential Score: 8/10\n\n- Three anti-Aβ antibodies now FDA-approved (Lecanemab, Donanemab, Aduhelm)\n- Active tau immunotherapy trials in progress\n- Earlier intervention correlates with better outcomes\n\n## Key Proteins and Genes\n\n| Protein/Gene | Role | Relevance |\n|--------------|------|-----------|\n| [APP](/genes/app) | Aβ precursor | Genetic cause of familial AD |\n| [PSEN1](/genes/psen1) | γ-secretase | Most common familial AD gene |\n| [PSEN2](/genes/psen2) | γ-secretase | Less common familial AD |\n| [APOE](/genes/apoe) | Lipid transport | Major genetic risk factor |\n| [TREM2](/genes/trem2) | Microglial receptor | Genetic risk factor (late onset) |\n| [MAPT](/genes/mapt) | Tau protein | Tau gene, risk for tauopathies |\n| [BIN1](/genes/bin1) | Bridging integrator | GWAS hit for sporadic AD |\n\n## Clinical Implications\n\n### Diagnostic Criteria\n\nThe NIA-AA research framework uses biomarker evidence:\n\n- **A+ (Amyloid positive):** PET or CSF evidence\n- **T+ (Tau positive):** PET or CSF evidence\n- **N+ (Neurodegeneration):** Atrophy, hypometabolism, or elevated t-tau\n\n\"AD\" is now defined by A+T+ status, regardless of clinical symptoms [17].\n\n### Biomarker Staging\n\n| Stage | Biomarkers | Clinical |\n|-------|-----------|----------|\n| Preclinical | A+ T- N- | Normal cognition |\n| MCI due to AD | A+ T+ N- | Mild impairment |\n| Dementia due to AD | A+ T+ N+ | Dementia |\n\n### Therapeutic Implications\n\n**Approved anti-amyloid therapies:**\n- **Lecanemab (Leqembi):** Aβ protofibril antibody, 27% slowing of decline [21]\n- **Donanemab (Kisunla):** N-terminal Aβ antibody, 35% slowing of decline [22]\n\n**In development:**\n- Tau immunotherapies (Semorinemab, Tilavonemab)\n- BACE inhibitors (stopped due to side effects)\n- Aggregation inhibitors\n\n## Related Hypotheses\n\n- [In Alzheimer's disease, biomarker events occur in a specific temporal sequence](/hypotheses/alzheimer's-disease,-biomarker-events-occur) — Aβ first, then tau, then neurodegeneration\n- [Amyloid plaque and neurofibrillary tangle deposition relationship](/hypotheses/amyloid-plaque-neurofibrillary-tangle-depositi) — mechanistic interaction\n- [Alterations in intra-regional functional connectivity](/hypotheses/hyp_146258) — Aβ and tau drive connectivity changes\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Amyloid-Beta](/proteins/amyloid-beta)\n- [Tau Protein](/proteins/tau)\n- [Amyloid Plaques](/mechanisms/dopaminergic-neuron-vulnerability)\n- [Neurofibrillary Tangles](/mechanisms/neurofibrillary-tangles)\n- [Senile Plaques](/mechanisms/dopaminergic-neuron-vulnerability)\n- [APP](/genes/app)\n- [Presenilin 1](/mechanisms/dopaminergic-neuron-vulnerability)\n- [Presenilin 2](/mechanisms/dopaminergic-neuron-vulnerability)\n- [APOE](/genes/apoe)\n- [Mild Cognitive Impairment](/investment/mci)\n\n## External Links\n\n- [Alzheimer's Association](https://www.alz.org/)\n- [Alzheimer's Disease Neuroimaging Initiative (ADNI)](https://adni.loni.usc.edu/)\n- [SEA-AD Project](https://www.alzheimers.gov/alzheimers-dementias/alzheimers-disease-brain-cell-atlas-sea-ad)\n- [Allen Institute for Brain Science](https://portal.brain-map.org/)\n\n## References\n\n1. [Unknown, Katzman R. Alzheimer's disease. *N Engl J Med*. 1988;314(15):964-973 (1988)](https://doi.org/10.1056/NEJM198804143141509)\n2. [Unknown, Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. *Nat Rev Mol Cell Biol*. 2007;8(2):101-112 (2007)](https://doi.org/10.1038/nrm2101)\n3. [Unknown, Jarrett JT, Berger EP, Lansbury PT Jr. The C-terminus of the beta protein is critical in amyloidogenesis. *Ann Neurol*. 1993;33(4):423-428 (1993)](https://doi.org/10.1002/ana.410330418)\n4. [Unknown, Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. *Proc Natl Acad Sci USA*. 1985;82(12):4245-4249 (1985)](https://doi.org/10.1073/pnas.82.12.4245)\n5. [Unknown, Dickson TC, Vickers JC. The morphological phenotype of beta-amyloid plaques and associated neuritic changes in Alzheimer's disease. *Neuroscience*. 2001;105(1):99-107 (2001)](https://doi.org/10.1016/S0306-4522(01)\n6. [Unknown, Mandelkow EM, Mandelkow E. Tau in physiology and pathology. *Nat Rev Neurosci*. 2014;15(1):25-39 (2014)](https://doi.org/10.1038/nrn3656)\n7. [Unknown, Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. *Trends Mol Med*. 2009;15(3):112-119 (2009)](https://doi.org/10.1016/j.molmed.2009.01.003)\n8. [Unknown, Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol*. 1991;82(4):239-259 (1991)](https://doi.org/10.1007/BF00308809)\n9. [Unknown, Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. *Science*. 1992;256(5054):184-185 (1992)](https://doi.org/10.1126/science.1566067)\n10. [Unknown, Götz J, Ittner LM, Lim YA. Animal models of Alzheimer's disease and frontotemporal dementia. *Nat Rev Neurosci*. 2008;9(11):853-864 (2008)](https://doi.org/10.1038/nrn2470)\n11. [Unknown, Ittner LM, Götz J. Amyloid-beta and tau—a toxic pas de deux in Alzheimer's disease. *Nat Rev Neurosci*. 2011;12(2):65-72 (2011)](https://doi.org/10.1038/nrn2967)\n12. [Unknown, De Strooper B, Karran E. The cellular phase of Alzheimer's disease. *Cell*. 2016;164(4):603-615 (2016)](https://doi.org/10.1016/j.cell.2015.11.057)\n13. [Goate A, Chartier-Harlin MC, Mullan M, et al., Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature*. 1991;349(6311):704-706 (1991)](https://doi.org/10.1038/349704a0)\n14. [Strittmatter WJ, Saunders AM, Schmechel D, et al., Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset Alzheimer disease. *Proc Natl Acad Sci USA*. 1993;90(5):1977-1981 (1993)](https://doi.org/10.1073/pnas.90.5.1977)\n15. [Jonsson T, Atwal JK, Steinberg S, et al., A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. *Nature*. 2012;488(7409):96-99 (2012)](https://doi.org/10.1038/nature11283)\n16. [Unknown, Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: current status and future prospects. *Nat Rev Drug Discov*. 2018;17(5):297-312 (2018)](https://doi.org/10.1038/nrd.2018.2)\n17. [Jack CR Jr, Bennett DA, Blennow K, et al., NIA-AA research framework: toward a biological definition of Alzheimer's disease. *Alzheimer's Dement*. 2018;14(4):535-562 (2018)](https://doi.org/10.1016/j.jalz.2018.02.018)\n18. [Palmqvist S, van der Giessen L, Stomrud E, et al., Blood biomarkers to detect early-stage Alzheimer's disease. *JAMA Neurol*. 2024;81(3):231-241 (2024)](https://doi.org/10.1001/jamaneurol.2023.5281)\n19. [Unknown, Jankord R, Kofman P. Transgenic mouse models of Alzheimer's disease: mechanisms and therapeutic potential. *Nat Rev Drug Discov*. 2024;23(3):201-218 (2024)](https://doi.org/10.1038/s41573-024-00872-7)\n20. [Unknown, Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition leads to synaptic deficits and cognitive decline in an Alzheimer's disease mouse model. *Neurobiol Aging*. 2003;24(7):997-1007 (2003)](https://doi.org/10.1016/j.neurobiolaging.2003.02.008)\n21. [van Dyck CH, Swanson CJ, Aisen P, et al., Lecanemab in early Alzheimer's disease. *N Engl J Med*. 2023;388(1):9-21 (2023)](https://doi.org/10.1056/NEJMoa2212948)\n22. [Sims JR, Zimmer JA, Evans CD, et al., Donanemab in early Alzheimer's disease. *N Engl J Med*. 2023;389(1):42-53 (2023)](https://doi.org/10.1056/NEJMoa2304840)",
  "entity_type": "hypothesis"
}

{
  "content_md": "## Mechanistic Model\n\n```mermaid\nflowchart TD\n    subgraph Amyloid_Pathogenesis[\"Amyloid-Beta Pathogenesis\"]\n        A[\"APP Proteolysis<br[\"beta-secretase, gamma-secretase\"\"]:::blue  -->  B[\"Abeta Monomer<br[\"Production\"\"]\n        B  -->  C{\"Abeta Aggregation<br[\"Threshold\"}\n        C  -->  D[\"Abeta Oligomers<br>Toxic Species\"\"]:::red\n        D  -->  E[\"Abeta Plaques<br[\"Diffuse & Core\"\"]:::red\n        E  -->  F[\"Dystrophic Neurites<br[\"Axonal Swelling\"\"]:::red\n    end\n\n    subgraph Tau_Pathogenesis[\"Tau Pathogenesis\"]\n        G[\"Normal Tau<br[\"Microtubule Binding\"\"]  -->  H[\"Hyperphosphorylation<br[\"AT8, AT100, PHF\"\"]\n        H  -->  I[\"Tau Misfolding<br[\"beta-sheet Formation\"\"]\n        I  -->  J[\"Paired Helical Filaments<br[\"PHFs\"\"]:::red\n        J  -->  K[\"Neurofibrillary<br[\"Tangles NFTs\"\"]:::red\n        K  -->  L[\"Neuronal Death<br[\"& Neurodegeneration\"\"]:::red\n    end\n\n    subgraph Neuronal_Impact[\"Neuronal Dysfunction\"]\n        D  -->  M[\"Synaptic Dysfunction<br[\"Spine Loss\"\"]:::orange\n        M  -->  N[\"Mitochondrial<br[\"Dysfunction\"\"]:::orange\n        N  -->  O[\"Calcium<br[\"Dysregulation\"\"]:::orange\n        O  -->  P[\"Oxidative<br[\"Stress\"\"]:::orange\n        P  -->  L\n    end\n\n    subgraph Therapeutic_Targets[\"Therapeutic Targets\"]\n        Q[\"Anti-Abeta Antibodies<br[\"Lecanemad, Donanemab\"\"]:::green  -->  D\n        R[\"BACE Inhibitors<br[\"Reduce Abeta production\"\"]:::green  -->  A\n        S[\"Anti-Tau Antibodies<br[\"Semorinemab\"\"]:::green  -->  K\n        T[\"Tau Aggregation<br[\"Inhibitors\"\"]:::green  -->  J\n    end\n\n    style A fill:#0a1929,stroke:#1565c0\n    style B fill:#0a1929,stroke:#1565c0\n    style C fill:#3e2200,stroke:#e65100\n    style D fill:#2d0f0f,stroke:#c62828\n    style E fill:#2d0f0f,stroke:#c62828\n    style F fill:#2d0f0f,stroke:#c62828\n    style G fill:#0a1f0a,stroke:#2e7d32\n    style H fill:#1e1e2e8e1,stroke:#f57f17\n    style I fill:#1e1e2e8e1,stroke:#f57f17\n    style J fill:#2d0f0f,stroke:#c62828\n    style K fill:#2d0f0f,stroke:#c62828\n    style L fill:#2d0f0f,stroke:#c62828\n    style M fill:#2d0f0f,stroke:#c2185b\n    style N fill:#2d0f0f,stroke:#c2185b\n    style O fill:#2d0f0f,stroke:#c2185b\n    style P fill:#2d0f0f,stroke:#c2185b\n    style Q fill:#0e2e10,stroke:#2e7d32\n    style R fill:#0e2e10,stroke:#2e7d32\n    style S fill:#0e2e10,stroke:#2e7d32\n    style T fill:#0e2e10,stroke:#2e7d32\n```\n\n## Overview\n\nThis hypothesis establishes that **Alzheimer's disease neuropathology is defined by the accumulation of pathological amyloid-beta (Aβ) in the form of senile plaques and dystrophic neurites, and phosphorylated tau neurofibrillary tangles (NFTs)** [1]. These two proteinaceous lesions form the pathological basis of the disease and drive the characteristic neurodegeneration and cognitive decline observed in [Alzheimer's Disease](/diseases/alzheimers-disease). [@ittner2011]\n\n**Type:** Disease Model [@strooper2016]\n\n**Confidence Level:** Established (Century-old consensus) [@goate1991]\n\n**Diseases Associated:** [Alzheimer's Disease](/diseases/alzheimers-disease), Down syndrome (trisomy 21), [Cerebral Amyloid Angiopathy](/diseases/cerebral-amyloid-angiopathy) [@strittmatter1993]\n\n## Amyloid-Beta Pathology\n\n### Production and Processing\n\n[Amyloid precursor protein (APP)](/genes/app) undergoes proteolytic processing via two pathways: [@jonsson2012]\n\n1. **Non-amyloidogenic pathway:** α-secretase cleavage produces sAPPα and CTFα, precluding Aβ formation\n2. **Amyloidogenic pathway:** β-secretase (BACE1) and γ-secretase cleavage produces Aβ peptides [2]\n\nThe γ-secretase complex includes: [@blennow2018]\n- [Presenilin 1 (PSEN1)](/genes/psen1) — catalytic subunit\n- [Presenilin 2 (PSEN2)](/genes/psen2) — alternate catalytic subunit\n- [Aph-1](/genes/aph1a), [Pen-2](/genes/pen2), [Nicastrin](/genes/ncstn) — accessory subunits\n\n### Aβ Peptide Species\n\n| Species | Length | Aggregation | Toxicity | [@jack2018]\n|---------|--------|-------------|----------| [@palmqvist2024]\n| Aβ1-38 | 38 aa | Low | Minimal | [@jankord2024]\n| Aβ1-40 | 40 aa | Moderate | Moderate | [@oddo2003]\n| Aβ1-42 | 42 aa | High | High | [@van2023]\n| Aβ1-43 | 43 aa | Very high | Very high | [@sims2023]\n\nAβ42 and Aβ43 are more aggregation-prone and form the core of senile plaques [3].\n\n### Plaque Types\n\n1. **Diffuse plaques:** Non-fibrillar Aβ deposits, often in pre-clinical stages\n2. **Core plaques:** Dense-core Aβ with neuritic components\n3. **Plaques with dystrophic neurites:** Neuronal processes surrounding plaques\n4. **Cerebral amyloid angiopathy (CAA):** Aβ deposition in blood vessel walls [4]\n\n### Dystrophic Neurites\n\nDystrophic neurites are swollen, tortuous neuronal processes surrounding amyloid plaques:\n\n- Accumulate in response to local Aβ toxicity\n- Contain phosphorylated tau, ubiquitin, and other proteins\n- Represent early sign of neuronal injury\n- Correlate with local synaptic loss [5]\n\n## Tau Pathology\n\n### Tau Biology\n\n[Tau](/proteins/tau) is a microtubule-associated protein encoded by the [MAPT](/genes/mapt) gene:\n\n- Six isoforms (0N3R to 4N4R) via alternative splicing\n- Binds to and stabilizes microtubules\n- Primarily expressed in neurons\n- Regulates axonal transport and synaptic function [6]\n\n### Hyperphosphorylation\n\nIn AD, tau becomes abnormally phosphorylated at >45 sites:\n\n**Key phosphorylation sites:**\n- Ser202/Thr205 (AT8 epitope)\n- Thr212/Ser214 (AT100 epitope)\n- Ser396/Ser404 (PHF-1 epitope)\n- Thr181 (CSF biomarker)\n\nKinases involved:\n- [GSK-3β](/proteins/gsk-3-beta) — primary tau kinase\n- [CDK5](/genes/cdk5r1) — neuronal tau kinase\n- MAPK family members [7]\n\n### Neurofibrillary Tangles\n\nNFTs consist of paired helical filaments (PHFs) and straight filaments:\n\n1. **Pretangles:** Soluble hyperphosphorylated tau in cytoplasm\n2. **Intracellular NFTs:** Fibrillar tau in neuronal soma\n3. **Extracellular NFTs:** \"Ghost tangles\" after neuron death\n\nNFTs follow a predictable anatomical progression (Braak staging) [8]:\n\n| Stage | Regions Affected | Clinical Correlation |\n|-------|------------------|---------------------|\n| I-II | Transentorhinal | Preclinical |\n| III-IV | Limbic (hippocampus, amygdala) | MCI |\n| V-VI | Isocortical | Dementia |\n\n## Relationship Between Aβ and Tau\n\n### The Amyloid Cascade Hypothesis\n\nThe amyloid cascade hypothesis posits that Aβ accumulation is the primary trigger:\n\n1. Aβ accumulation → synaptic dysfunction\n2. Synaptic loss → tau hyperphosphorylation\n3. NFT formation → neuronal death\n4. Neurodegeneration → cognitive decline [9]\n\n### Evidence for Aβ-Tau Interaction\n\n**Supporting evidence:**\n- Aβ promotes tau pathology in animal models [10]\n- Tau facilitates Aβ toxicity [11]\n- Spatial correlation between plaques and NFTs\n- Genetic evidence (APP, PSEN1, PSEN2, APOE)\n\n**Challenging evidence:**\n- Plaque burden doesn't correlate with cognitive decline\n- NFT burden strongly correlates with cognitive status\n- Aβ-independent tauopathies exist\n- Many elderly have plaques without dementia\n\n### Updated Model: Multi-hit Hypothesis\n\nCurrent models suggest Aβ initiates a cascade, but multiple factors determine progression:\n\n- Aβ as an \"amplifier\" rather than sole cause\n- Tau spread via trans-synaptic mechanisms\n- Role of neuroinflammation, glial activation\n- Genetic modifiers (APOE, [TREM2](/genes/trem2)) [12]\n\n## Evidence Assessment\n\n### Confidence Level: Established\n\n| Evidence Type | Strength | Key Studies |\n|---------------|----------|-------------|\n| Histopathology | Strong | [1, 4, 8] |\n| Genetic Studies | Strong | [13, 14, 15] |\n| Biomarker Studies | Strong | [16, 17, 18] |\n| Animal Models | Strong | [19, 20] |\n| Clinical Trials | Moderate | [21, 22] |\n\n### Key Supporting Studies\n\n1. **Katzman (1988)** — Established Aβ plaques and NFTs as the defining lesions of AD [1]\n2. **Goate et al. (1991)** — First PSEN1 mutation linked to familial AD [13]\n3. **Strittmatter et al. (1993)** — APOE ε4 as major genetic risk factor [14]\n4. **Braak & Braak (1991)** — Systematic staging of NFT pathology [8]\n5. **Jack et al. (2018)** — AT(N) biomarker classification framework [17]\n\n### Testability Score: 10/10\n\n- Post-mortem histopathology definitively identifies both lesions\n- PET ligands detect plaques (Flutemetamol, Florbetapir) and tau (Flortaucipir) in vivo\n- CSF biomarkers measure Aβ42, total tau, and phosphorylated tau\n- Multiple therapeutic trials target Aβ and tau\n\n### Therapeutic Potential Score: 8/10\n\n- Three anti-Aβ antibodies now FDA-approved (Lecanemab, Donanemab, Aduhelm)\n- Active tau immunotherapy trials in progress\n- Earlier intervention correlates with better outcomes\n\n## Key Proteins and Genes\n\n| Protein/Gene | Role | Relevance |\n|--------------|------|-----------|\n| [APP](/genes/app) | Aβ precursor | Genetic cause of familial AD |\n| [PSEN1](/genes/psen1) | γ-secretase | Most common familial AD gene |\n| [PSEN2](/genes/psen2) | γ-secretase | Less common familial AD |\n| [APOE](/genes/apoe) | Lipid transport | Major genetic risk factor |\n| [TREM2](/genes/trem2) | Microglial receptor | Genetic risk factor (late onset) |\n| [MAPT](/genes/mapt) | Tau protein | Tau gene, risk for tauopathies |\n| [BIN1](/genes/bin1) | Bridging integrator | GWAS hit for sporadic AD |\n\n## Clinical Implications\n\n### Diagnostic Criteria\n\nThe NIA-AA research framework uses biomarker evidence:\n\n- **A+ (Amyloid positive):** PET or CSF evidence\n- **T+ (Tau positive):** PET or CSF evidence\n- **N+ (Neurodegeneration):** Atrophy, hypometabolism, or elevated t-tau\n\n\"AD\" is now defined by A+T+ status, regardless of clinical symptoms [17].\n\n### Biomarker Staging\n\n| Stage | Biomarkers | Clinical |\n|-------|-----------|----------|\n| Preclinical | A+ T- N- | Normal cognition |\n| MCI due to AD | A+ T+ N- | Mild impairment |\n| Dementia due to AD | A+ T+ N+ | Dementia |\n\n### Therapeutic Implications\n\n**Approved anti-amyloid therapies:**\n- **Lecanemab (Leqembi):** Aβ protofibril antibody, 27% slowing of decline [21]\n- **Donanemab (Kisunla):** N-terminal Aβ antibody, 35% slowing of decline [22]\n\n**In development:**\n- Tau immunotherapies (Semorinemab, Tilavonemab)\n- BACE inhibitors (stopped due to side effects)\n- Aggregation inhibitors\n\n## Related Hypotheses\n\n- [In Alzheimer's disease, biomarker events occur in a specific temporal sequence](/hypotheses/alzheimer's-disease,-biomarker-events-occur) — Aβ first, then tau, then neurodegeneration\n- [Amyloid plaque and neurofibrillary tangle deposition relationship](/hypotheses/amyloid-plaque-neurofibrillary-tangle-depositi) — mechanistic interaction\n- [Alterations in intra-regional functional connectivity](/hypotheses/hyp_146258) — Aβ and tau drive connectivity changes\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Amyloid-Beta](/proteins/amyloid-beta)\n- [Tau Protein](/proteins/tau)\n- [Amyloid Plaques](/mechanisms/dopaminergic-neuron-vulnerability)\n- [Neurofibrillary Tangles](/mechanisms/neurofibrillary-tangles)\n- [Senile Plaques](/mechanisms/dopaminergic-neuron-vulnerability)\n- [APP](/genes/app)\n- [Presenilin 1](/mechanisms/dopaminergic-neuron-vulnerability)\n- [Presenilin 2](/mechanisms/dopaminergic-neuron-vulnerability)\n- [APOE](/genes/apoe)\n- [Mild Cognitive Impairment](/investment/mci)\n\n## External Links\n\n- [Alzheimer's Association](https://www.alz.org/)\n- [Alzheimer's Disease Neuroimaging Initiative (ADNI)](https://adni.loni.usc.edu/)\n- [SEA-AD Project](https://www.alzheimers.gov/alzheimers-dementias/alzheimers-disease-brain-cell-atlas-sea-ad)\n- [Allen Institute for Brain Science](https://portal.brain-map.org/)\n\n## References\n\n1. [Unknown, Katzman R. Alzheimer's disease. *N Engl J Med*. 1988;314(15):964-973 (1988)](https://doi.org/10.1056/NEJM198804143141509)\n2. [Unknown, Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. *Nat Rev Mol Cell Biol*. 2007;8(2):101-112 (2007)](https://doi.org/10.1038/nrm2101)\n3. [Unknown, Jarrett JT, Berger EP, Lansbury PT Jr. The C-terminus of the beta protein is critical in amyloidogenesis. *Ann Neurol*. 1993;33(4):423-428 (1993)](https://doi.org/10.1002/ana.410330418)\n4. [Unknown, Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. *Proc Natl Acad Sci USA*. 1985;82(12):4245-4249 (1985)](https://doi.org/10.1073/pnas.82.12.4245)\n5. [Unknown, Dickson TC, Vickers JC. The morphological phenotype of beta-amyloid plaques and associated neuritic changes in Alzheimer's disease. *Neuroscience*. 2001;105(1):99-107 (2001)](https://doi.org/10.1016/S0306-4522(01)\n6. [Unknown, Mandelkow EM, Mandelkow E. Tau in physiology and pathology. *Nat Rev Neurosci*. 2014;15(1):25-39 (2014)](https://doi.org/10.1038/nrn3656)\n7. [Unknown, Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. *Trends Mol Med*. 2009;15(3):112-119 (2009)](https://doi.org/10.1016/j.molmed.2009.01.003)\n8. [Unknown, Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol*. 1991;82(4):239-259 (1991)](https://doi.org/10.1007/BF00308809)\n9. [Unknown, Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. *Science*. 1992;256(5054):184-185 (1992)](https://doi.org/10.1126/science.1566067)\n10. [Unknown, Götz J, Ittner LM, Lim YA. Animal models of Alzheimer's disease and frontotemporal dementia. *Nat Rev Neurosci*. 2008;9(11):853-864 (2008)](https://doi.org/10.1038/nrn2470)\n11. [Unknown, Ittner LM, Götz J. Amyloid-beta and tau—a toxic pas de deux in Alzheimer's disease. *Nat Rev Neurosci*. 2011;12(2):65-72 (2011)](https://doi.org/10.1038/nrn2967)\n12. [Unknown, De Strooper B, Karran E. The cellular phase of Alzheimer's disease. *Cell*. 2016;164(4):603-615 (2016)](https://doi.org/10.1016/j.cell.2015.11.057)\n13. [Goate A, Chartier-Harlin MC, Mullan M, et al., Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature*. 1991;349(6311):704-706 (1991)](https://doi.org/10.1038/349704a0)\n14. [Strittmatter WJ, Saunders AM, Schmechel D, et al., Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset Alzheimer disease. *Proc Natl Acad Sci USA*. 1993;90(5):1977-1981 (1993)](https://doi.org/10.1073/pnas.90.5.1977)\n15. [Jonsson T, Atwal JK, Steinberg S, et al., A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. *Nature*. 2012;488(7409):96-99 (2012)](https://doi.org/10.1038/nature11283)\n16. [Unknown, Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: current status and future prospects. *Nat Rev Drug Discov*. 2018;17(5):297-312 (2018)](https://doi.org/10.1038/nrd.2018.2)\n17. [Jack CR Jr, Bennett DA, Blennow K, et al., NIA-AA research framework: toward a biological definition of Alzheimer's disease. *Alzheimer's Dement*. 2018;14(4):535-562 (2018)](https://doi.org/10.1016/j.jalz.2018.02.018)\n18. [Palmqvist S, van der Giessen L, Stomrud E, et al., Blood biomarkers to detect early-stage Alzheimer's disease. *JAMA Neurol*. 2024;81(3):231-241 (2024)](https://doi.org/10.1001/jamaneurol.2023.5281)\n19. [Unknown, Jankord R, Kofman P. Transgenic mouse models of Alzheimer's disease: mechanisms and therapeutic potential. *Nat Rev Drug Discov*. 2024;23(3):201-218 (2024)](https://doi.org/10.1038/s41573-024-00872-7)\n20. [Unknown, Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition leads to synaptic deficits and cognitive decline in an Alzheimer's disease mouse model. *Neurobiol Aging*. 2003;24(7):997-1007 (2003)](https://doi.org/10.1016/j.neurobiolaging.2003.02.008)\n21. [van Dyck CH, Swanson CJ, Aisen P, et al., Lecanemab in early Alzheimer's disease. *N Engl J Med*. 2023;388(1):9-21 (2023)](https://doi.org/10.1056/NEJMoa2212948)\n22. [Sims JR, Zimmer JA, Evans CD, et al., Donanemab in early Alzheimer's disease. *N Engl J Med*. 2023;389(1):42-53 (2023)](https://doi.org/10.1056/NEJMoa2304840)",
  "entity_type": "hypothesis"
}

{
  "content_md": "## Mechanistic Model\n\n```mermaid\nflowchart TD\n    subgraph Amyloid_Pathogenesis[\"Amyloid-Beta Pathogenesis\"]\n        A[\"APP Proteolysis<br[\"β-secretase, γ-secretase\"\"]:::blue  -->  B[\"Aβ Monomer<br[\"Production\"\"]\n        B  -->  C{\"Aβ Aggregation<br[\"Threshold\"}\n        C  -->  D[\"Aβ Oligomers<br>Toxic Species\"\"]:::red\n        D  -->  E[\"Aβ Plaques<br[\"Diffuse & Core\"\"]:::red\n        E  -->  F[\"Dystrophic Neurites<br[\"Axonal Swelling\"\"]:::red\n    end\n\n    subgraph Tau_Pathogenesis[\"Tau Pathogenesis\"]\n        G[\"Normal Tau<br[\"Microtubule Binding\"\"]  -->  H[\"Hyperphosphorylation<br[\"AT8, AT100, PHF\"\"]\n        H  -->  I[\"Tau Misfolding<br[\"β-sheet Formation\"\"]\n        I  -->  J[\"Paired Helical Filaments<br[\"PHFs\"\"]:::red\n        J  -->  K[\"Neurofibrillary<br[\"Tangles NFTs\"\"]:::red\n        K  -->  L[\"Neuronal Death<br[\"& Neurodegeneration\"\"]:::red\n    end\n\n    subgraph Neuronal_Impact[\"Neuronal Dysfunction\"]\n        D  -->  M[\"Synaptic Dysfunction<br[\"Spine Loss\"\"]:::orange\n        M  -->  N[\"Mitochondrial<br[\"Dysfunction\"\"]:::orange\n        N  -->  O[\"Calcium<br[\"Dysregulation\"\"]:::orange\n        O  -->  P[\"Oxidative<br[\"Stress\"\"]:::orange\n        P  -->  L\n    end\n\n    subgraph Therapeutic_Targets[\"Therapeutic Targets\"]\n        Q[\"Anti-Aβ Antibodies<br[\"Lecanemad, Donanemab\"\"]:::green  -->  D\n        R[\"BACE Inhibitors<br[\"Reduce Aβ production\"\"]:::green  -->  A\n        S[\"Anti-Tau Antibodies<br[\"Semorinemab\"\"]:::green  -->  K\n        T[\"Tau Aggregation<br[\"Inhibitors\"\"]:::green  -->  J\n    end\n\n    style A fill:#0a1929,stroke:#1565c0\n    style B fill:#0a1929,stroke:#1565c0\n    style C fill:#3e2200,stroke:#e65100\n    style D fill:#2d0f0f,stroke:#c62828\n    style E fill:#2d0f0f,stroke:#c62828\n    style F fill:#2d0f0f,stroke:#c62828\n    style G fill:#0a1f0a,stroke:#2e7d32\n    style H fill:#1e1e2e8e1,stroke:#f57f17\n    style I fill:#1e1e2e8e1,stroke:#f57f17\n    style J fill:#2d0f0f,stroke:#c62828\n    style K fill:#2d0f0f,stroke:#c62828\n    style L fill:#2d0f0f,stroke:#c62828\n    style M fill:#2d0f0f,stroke:#c2185b\n    style N fill:#2d0f0f,stroke:#c2185b\n    style O fill:#2d0f0f,stroke:#c2185b\n    style P fill:#2d0f0f,stroke:#c2185b\n    style Q fill:#0e2e10,stroke:#2e7d32\n    style R fill:#0e2e10,stroke:#2e7d32\n    style S fill:#0e2e10,stroke:#2e7d32\n    style T fill:#0e2e10,stroke:#2e7d32\n```\n\n## Overview\n\nThis hypothesis establishes that **Alzheimer's disease neuropathology is defined by the accumulation of pathological amyloid-beta (Aβ) in the form of senile plaques and dystrophic neurites, and phosphorylated tau neurofibrillary tangles (NFTs)** [1]. These two proteinaceous lesions form the pathological basis of the disease and drive the characteristic neurodegeneration and cognitive decline observed in [Alzheimer's Disease](/diseases/alzheimers-disease). [@ittner2011]\n\n**Type:** Disease Model [@strooper2016]\n\n**Confidence Level:** Established (Century-old consensus) [@goate1991]\n\n**Diseases Associated:** [Alzheimer's Disease](/diseases/alzheimers-disease), Down syndrome (trisomy 21), [Cerebral Amyloid Angiopathy](/diseases/cerebral-amyloid-angiopathy) [@strittmatter1993]\n\n## Amyloid-Beta Pathology\n\n### Production and Processing\n\n[Amyloid precursor protein (APP)](/genes/app) undergoes proteolytic processing via two pathways: [@jonsson2012]\n\n1. **Non-amyloidogenic pathway:** α-secretase cleavage produces sAPPα and CTFα, precluding Aβ formation\n2. **Amyloidogenic pathway:** β-secretase (BACE1) and γ-secretase cleavage produces Aβ peptides [2]\n\nThe γ-secretase complex includes: [@blennow2018]\n- [Presenilin 1 (PSEN1)](/genes/psen1) — catalytic subunit\n- [Presenilin 2 (PSEN2)](/genes/psen2) — alternate catalytic subunit\n- [Aph-1](/genes/aph1a), [Pen-2](/genes/pen2), [Nicastrin](/genes/ncstn) — accessory subunits\n\n### Aβ Peptide Species\n\n| Species | Length | Aggregation | Toxicity | [@jack2018]\n|---------|--------|-------------|----------| [@palmqvist2024]\n| Aβ1-38 | 38 aa | Low | Minimal | [@jankord2024]\n| Aβ1-40 | 40 aa | Moderate | Moderate | [@oddo2003]\n| Aβ1-42 | 42 aa | High | High | [@van2023]\n| Aβ1-43 | 43 aa | Very high | Very high | [@sims2023]\n\nAβ42 and Aβ43 are more aggregation-prone and form the core of senile plaques [3].\n\n### Plaque Types\n\n1. **Diffuse plaques:** Non-fibrillar Aβ deposits, often in pre-clinical stages\n2. **Core plaques:** Dense-core Aβ with neuritic components\n3. **Plaques with dystrophic neurites:** Neuronal processes surrounding plaques\n4. **Cerebral amyloid angiopathy (CAA):** Aβ deposition in blood vessel walls [4]\n\n### Dystrophic Neurites\n\nDystrophic neurites are swollen, tortuous neuronal processes surrounding amyloid plaques:\n\n- Accumulate in response to local Aβ toxicity\n- Contain phosphorylated tau, ubiquitin, and other proteins\n- Represent early sign of neuronal injury\n- Correlate with local synaptic loss [5]\n\n## Tau Pathology\n\n### Tau Biology\n\n[Tau](/proteins/tau) is a microtubule-associated protein encoded by the [MAPT](/genes/mapt) gene:\n\n- Six isoforms (0N3R to 4N4R) via alternative splicing\n- Binds to and stabilizes microtubules\n- Primarily expressed in neurons\n- Regulates axonal transport and synaptic function [6]\n\n### Hyperphosphorylation\n\nIn AD, tau becomes abnormally phosphorylated at >45 sites:\n\n**Key phosphorylation sites:**\n- Ser202/Thr205 (AT8 epitope)\n- Thr212/Ser214 (AT100 epitope)\n- Ser396/Ser404 (PHF-1 epitope)\n- Thr181 (CSF biomarker)\n\nKinases involved:\n- [GSK-3β](/proteins/gsk-3-beta) — primary tau kinase\n- [CDK5](/genes/cdk5r1) — neuronal tau kinase\n- MAPK family members [7]\n\n### Neurofibrillary Tangles\n\nNFTs consist of paired helical filaments (PHFs) and straight filaments:\n\n1. **Pretangles:** Soluble hyperphosphorylated tau in cytoplasm\n2. **Intracellular NFTs:** Fibrillar tau in neuronal soma\n3. **Extracellular NFTs:** \"Ghost tangles\" after neuron death\n\nNFTs follow a predictable anatomical progression (Braak staging) [8]:\n\n| Stage | Regions Affected | Clinical Correlation |\n|-------|------------------|---------------------|\n| I-II | Transentorhinal | Preclinical |\n| III-IV | Limbic (hippocampus, amygdala) | MCI |\n| V-VI | Isocortical | Dementia |\n\n## Relationship Between Aβ and Tau\n\n### The Amyloid Cascade Hypothesis\n\nThe amyloid cascade hypothesis posits that Aβ accumulation is the primary trigger:\n\n1. Aβ accumulation → synaptic dysfunction\n2. Synaptic loss → tau hyperphosphorylation\n3. NFT formation → neuronal death\n4. Neurodegeneration → cognitive decline [9]\n\n### Evidence for Aβ-Tau Interaction\n\n**Supporting evidence:**\n- Aβ promotes tau pathology in animal models [10]\n- Tau facilitates Aβ toxicity [11]\n- Spatial correlation between plaques and NFTs\n- Genetic evidence (APP, PSEN1, PSEN2, APOE)\n\n**Challenging evidence:**\n- Plaque burden doesn't correlate with cognitive decline\n- NFT burden strongly correlates with cognitive status\n- Aβ-independent tauopathies exist\n- Many elderly have plaques without dementia\n\n### Updated Model: Multi-hit Hypothesis\n\nCurrent models suggest Aβ initiates a cascade, but multiple factors determine progression:\n\n- Aβ as an \"amplifier\" rather than sole cause\n- Tau spread via trans-synaptic mechanisms\n- Role of neuroinflammation, glial activation\n- Genetic modifiers (APOE, [TREM2](/genes/trem2)) [12]\n\n## Evidence Assessment\n\n### Confidence Level: Established\n\n| Evidence Type | Strength | Key Studies |\n|---------------|----------|-------------|\n| Histopathology | Strong | [1, 4, 8] |\n| Genetic Studies | Strong | [13, 14, 15] |\n| Biomarker Studies | Strong | [16, 17, 18] |\n| Animal Models | Strong | [19, 20] |\n| Clinical Trials | Moderate | [21, 22] |\n\n### Key Supporting Studies\n\n1. **Katzman (1988)** — Established Aβ plaques and NFTs as the defining lesions of AD [1]\n2. **Goate et al. (1991)** — First PSEN1 mutation linked to familial AD [13]\n3. **Strittmatter et al. (1993)** — APOE ε4 as major genetic risk factor [14]\n4. **Braak & Braak (1991)** — Systematic staging of NFT pathology [8]\n5. **Jack et al. (2018)** — AT(N) biomarker classification framework [17]\n\n### Testability Score: 10/10\n\n- Post-mortem histopathology definitively identifies both lesions\n- PET ligands detect plaques (Flutemetamol, Florbetapir) and tau (Flortaucipir) in vivo\n- CSF biomarkers measure Aβ42, total tau, and phosphorylated tau\n- Multiple therapeutic trials target Aβ and tau\n\n### Therapeutic Potential Score: 8/10\n\n- Three anti-Aβ antibodies now FDA-approved (Lecanemab, Donanemab, Aduhelm)\n- Active tau immunotherapy trials in progress\n- Earlier intervention correlates with better outcomes\n\n## Key Proteins and Genes\n\n| Protein/Gene | Role | Relevance |\n|--------------|------|-----------|\n| [APP](/genes/app) | Aβ precursor | Genetic cause of familial AD |\n| [PSEN1](/genes/psen1) | γ-secretase | Most common familial AD gene |\n| [PSEN2](/genes/psen2) | γ-secretase | Less common familial AD |\n| [APOE](/genes/apoe) | Lipid transport | Major genetic risk factor |\n| [TREM2](/genes/trem2) | Microglial receptor | Genetic risk factor (late onset) |\n| [MAPT](/genes/mapt) | Tau protein | Tau gene, risk for tauopathies |\n| [BIN1](/genes/bin1) | Bridging integrator | GWAS hit for sporadic AD |\n\n## Clinical Implications\n\n### Diagnostic Criteria\n\nThe NIA-AA research framework uses biomarker evidence:\n\n- **A+ (Amyloid positive):** PET or CSF evidence\n- **T+ (Tau positive):** PET or CSF evidence\n- **N+ (Neurodegeneration):** Atrophy, hypometabolism, or elevated t-tau\n\n\"AD\" is now defined by A+T+ status, regardless of clinical symptoms [17].\n\n### Biomarker Staging\n\n| Stage | Biomarkers | Clinical |\n|-------|-----------|----------|\n| Preclinical | A+ T- N- | Normal cognition |\n| MCI due to AD | A+ T+ N- | Mild impairment |\n| Dementia due to AD | A+ T+ N+ | Dementia |\n\n### Therapeutic Implications\n\n**Approved anti-amyloid therapies:**\n- **Lecanemab (Leqembi):** Aβ protofibril antibody, 27% slowing of decline [21]\n- **Donanemab (Kisunla):** N-terminal Aβ antibody, 35% slowing of decline [22]\n\n**In development:**\n- Tau immunotherapies (Semorinemab, Tilavonemab)\n- BACE inhibitors (stopped due to side effects)\n- Aggregation inhibitors\n\n## Related Hypotheses\n\n- [In Alzheimer's disease, biomarker events occur in a specific temporal sequence](/hypotheses/alzheimer's-disease,-biomarker-events-occur) — Aβ first, then tau, then neurodegeneration\n- [Amyloid plaque and neurofibrillary tangle deposition relationship](/hypotheses/amyloid-plaque-neurofibrillary-tangle-depositi) — mechanistic interaction\n- [Alterations in intra-regional functional connectivity](/hypotheses/hyp_146258) — Aβ and tau drive connectivity changes\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Amyloid-Beta](/proteins/amyloid-beta)\n- [Tau Protein](/proteins/tau)\n- [Amyloid Plaques](/mechanisms/dopaminergic-neuron-vulnerability)\n- [Neurofibrillary Tangles](/mechanisms/neurofibrillary-tangles)\n- [Senile Plaques](/mechanisms/dopaminergic-neuron-vulnerability)\n- [APP](/genes/app)\n- [Presenilin 1](/mechanisms/dopaminergic-neuron-vulnerability)\n- [Presenilin 2](/mechanisms/dopaminergic-neuron-vulnerability)\n- [APOE](/genes/apoe)\n- [Mild Cognitive Impairment](/investment/mci)\n\n## External Links\n\n- [Alzheimer's Association](https://www.alz.org/)\n- [Alzheimer's Disease Neuroimaging Initiative (ADNI)](https://adni.loni.usc.edu/)\n- [SEA-AD Project](https://www.alzheimers.gov/alzheimers-dementias/alzheimers-disease-brain-cell-atlas-sea-ad)\n- [Allen Institute for Brain Science](https://portal.brain-map.org/)\n\n## References\n\n1. [Unknown, Katzman R. Alzheimer's disease. *N Engl J Med*. 1988;314(15):964-973 (1988)](https://doi.org/10.1056/NEJM198804143141509)\n2. [Unknown, Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. *Nat Rev Mol Cell Biol*. 2007;8(2):101-112 (2007)](https://doi.org/10.1038/nrm2101)\n3. [Unknown, Jarrett JT, Berger EP, Lansbury PT Jr. The C-terminus of the beta protein is critical in amyloidogenesis. *Ann Neurol*. 1993;33(4):423-428 (1993)](https://doi.org/10.1002/ana.410330418)\n4. [Unknown, Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. *Proc Natl Acad Sci USA*. 1985;82(12):4245-4249 (1985)](https://doi.org/10.1073/pnas.82.12.4245)\n5. [Unknown, Dickson TC, Vickers JC. The morphological phenotype of beta-amyloid plaques and associated neuritic changes in Alzheimer's disease. *Neuroscience*. 2001;105(1):99-107 (2001)](https://doi.org/10.1016/S0306-4522(01)\n6. [Unknown, Mandelkow EM, Mandelkow E. Tau in physiology and pathology. *Nat Rev Neurosci*. 2014;15(1):25-39 (2014)](https://doi.org/10.1038/nrn3656)\n7. [Unknown, Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. *Trends Mol Med*. 2009;15(3):112-119 (2009)](https://doi.org/10.1016/j.molmed.2009.01.003)\n8. [Unknown, Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol*. 1991;82(4):239-259 (1991)](https://doi.org/10.1007/BF00308809)\n9. [Unknown, Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. *Science*. 1992;256(5054):184-185 (1992)](https://doi.org/10.1126/science.1566067)\n10. [Unknown, Götz J, Ittner LM, Lim YA. Animal models of Alzheimer's disease and frontotemporal dementia. *Nat Rev Neurosci*. 2008;9(11):853-864 (2008)](https://doi.org/10.1038/nrn2470)\n11. [Unknown, Ittner LM, Götz J. Amyloid-beta and tau—a toxic pas de deux in Alzheimer's disease. *Nat Rev Neurosci*. 2011;12(2):65-72 (2011)](https://doi.org/10.1038/nrn2967)\n12. [Unknown, De Strooper B, Karran E. The cellular phase of Alzheimer's disease. *Cell*. 2016;164(4):603-615 (2016)](https://doi.org/10.1016/j.cell.2015.11.057)\n13. [Goate A, Chartier-Harlin MC, Mullan M, et al., Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature*. 1991;349(6311):704-706 (1991)](https://doi.org/10.1038/349704a0)\n14. [Strittmatter WJ, Saunders AM, Schmechel D, et al., Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset Alzheimer disease. *Proc Natl Acad Sci USA*. 1993;90(5):1977-1981 (1993)](https://doi.org/10.1073/pnas.90.5.1977)\n15. [Jonsson T, Atwal JK, Steinberg S, et al., A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. *Nature*. 2012;488(7409):96-99 (2012)](https://doi.org/10.1038/nature11283)\n16. [Unknown, Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: current status and future prospects. *Nat Rev Drug Discov*. 2018;17(5):297-312 (2018)](https://doi.org/10.1038/nrd.2018.2)\n17. [Jack CR Jr, Bennett DA, Blennow K, et al., NIA-AA research framework: toward a biological definition of Alzheimer's disease. *Alzheimer's Dement*. 2018;14(4):535-562 (2018)](https://doi.org/10.1016/j.jalz.2018.02.018)\n18. [Palmqvist S, van der Giessen L, Stomrud E, et al., Blood biomarkers to detect early-stage Alzheimer's disease. *JAMA Neurol*. 2024;81(3):231-241 (2024)](https://doi.org/10.1001/jamaneurol.2023.5281)\n19. [Unknown, Jankord R, Kofman P. Transgenic mouse models of Alzheimer's disease: mechanisms and therapeutic potential. *Nat Rev Drug Discov*. 2024;23(3):201-218 (2024)](https://doi.org/10.1038/s41573-024-00872-7)\n20. [Unknown, Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition leads to synaptic deficits and cognitive decline in an Alzheimer's disease mouse model. *Neurobiol Aging*. 2003;24(7):997-1007 (2003)](https://doi.org/10.1016/j.neurobiolaging.2003.02.008)\n21. [van Dyck CH, Swanson CJ, Aisen P, et al., Lecanemab in early Alzheimer's disease. *N Engl J Med*. 2023;388(1):9-21 (2023)](https://doi.org/10.1056/NEJMoa2212948)\n22. [Sims JR, Zimmer JA, Evans CD, et al., Donanemab in early Alzheimer's disease. *N Engl J Med*. 2023;389(1):42-53 (2023)](https://doi.org/10.1056/NEJMoa2304840)",
  "entity_type": "hypothesis"
}

{
  "content_md": "## Mechanistic Model\n\n```mermaid\nflowchart TD\n    subgraph Amyloid_Pathogenesis[\"Amyloid-Beta Pathogenesis\"]\n        A[\"APP Proteolysis<br[\"beta-secretase, gamma-secretase\"\"]:::blue  -->  B[\"Abeta Monomer<br[\"Production\"\"]\n        B  -->  C{\"Abeta Aggregation<br[\"Threshold\"}\n        C  -->  D[\"Abeta Oligomers<br>Toxic Species\"\"]:::red\n        D  -->  E[\"Abeta Plaques<br[\"Diffuse & Core\"\"]:::red\n        E  -->  F[\"Dystrophic Neurites<br[\"Axonal Swelling\"\"]:::red\n    end\n\n    subgraph Tau_Pathogenesis[\"Tau Pathogenesis\"]\n        G[\"Normal Tau<br[\"Microtubule Binding\"\"]  -->  H[\"Hyperphosphorylation<br[\"AT8, AT100, PHF\"\"]\n        H  -->  I[\"Tau Misfolding<br[\"beta-sheet Formation\"\"]\n        I  -->  J[\"Paired Helical Filaments<br[\"PHFs\"\"]:::red\n        J  -->  K[\"Neurofibrillary<br[\"Tangles NFTs\"\"]:::red\n        K  -->  L[\"Neuronal Death<br[\"& Neurodegeneration\"\"]:::red\n    end\n\n    subgraph Neuronal_Impact[\"Neuronal Dysfunction\"]\n        D  -->  M[\"Synaptic Dysfunction<br[\"Spine Loss\"\"]:::orange\n        M  -->  N[\"Mitochondrial<br[\"Dysfunction\"\"]:::orange\n        N  -->  O[\"Calcium<br[\"Dysregulation\"\"]:::orange\n        O  -->  P[\"Oxidative<br[\"Stress\"\"]:::orange\n        P  -->  L\n    end\n\n    subgraph Therapeutic_Targets[\"Therapeutic Targets\"]\n        Q[\"Anti-Abeta Antibodies<br[\"Lecanemad, Donanemab\"\"]:::green  -->  D\n        R[\"BACE Inhibitors<br[\"Reduce Abeta production\"\"]:::green  -->  A\n        S[\"Anti-Tau Antibodies<br[\"Semorinemab\"\"]:::green  -->  K\n        T[\"Tau Aggregation<br[\"Inhibitors\"\"]:::green  -->  J\n    end\n\n    style A fill:#0a1929,stroke:#1565c0\n    style B fill:#0a1929,stroke:#1565c0\n    style C fill:#3e2200,stroke:#e65100\n    style D fill:#2d0f0f,stroke:#c62828\n    style E fill:#2d0f0f,stroke:#c62828\n    style F fill:#2d0f0f,stroke:#c62828\n    style G fill:#0a1f0a,stroke:#2e7d32\n    style H fill:#1e1e2e8e1,stroke:#f57f17\n    style I fill:#1e1e2e8e1,stroke:#f57f17\n    style J fill:#2d0f0f,stroke:#c62828\n    style K fill:#2d0f0f,stroke:#c62828\n    style L fill:#2d0f0f,stroke:#c62828\n    style M fill:#2d0f0f,stroke:#c2185b\n    style N fill:#2d0f0f,stroke:#c2185b\n    style O fill:#2d0f0f,stroke:#c2185b\n    style P fill:#2d0f0f,stroke:#c2185b\n    style Q fill:#0e2e10,stroke:#2e7d32\n    style R fill:#0e2e10,stroke:#2e7d32\n    style S fill:#0e2e10,stroke:#2e7d32\n    style T fill:#0e2e10,stroke:#2e7d32\n```\n\n## Overview\n\nThis hypothesis establishes that **Alzheimer's disease neuropathology is defined by the accumulation of pathological amyloid-beta (Aβ) in the form of senile plaques and dystrophic neurites, and phosphorylated tau neurofibrillary tangles (NFTs)** [1]. These two proteinaceous lesions form the pathological basis of the disease and drive the characteristic neurodegeneration and cognitive decline observed in [Alzheimer's Disease](/diseases/alzheimers-disease). [@ittner2011]\n\n**Type:** Disease Model [@strooper2016]\n\n**Confidence Level:** Established (Century-old consensus) [@goate1991]\n\n**Diseases Associated:** [Alzheimer's Disease](/diseases/alzheimers-disease), Down syndrome (trisomy 21), [Cerebral Amyloid Angiopathy](/diseases/cerebral-amyloid-angiopathy) [@strittmatter1993]\n\n## Amyloid-Beta Pathology\n\n### Production and Processing\n\n[Amyloid precursor protein (APP)](/genes/app) undergoes proteolytic processing via two pathways: [@jonsson2012]\n\n1. **Non-amyloidogenic pathway:** α-secretase cleavage produces sAPPα and CTFα, precluding Aβ formation\n2. **Amyloidogenic pathway:** β-secretase (BACE1) and γ-secretase cleavage produces Aβ peptides [2]\n\nThe γ-secretase complex includes: [@blennow2018]\n- [Presenilin 1 (PSEN1)](/genes/psen1) — catalytic subunit\n- [Presenilin 2 (PSEN2)](/genes/psen2) — alternate catalytic subunit\n- [Aph-1](/genes/aph1a), [Pen-2](/genes/pen2), [Nicastrin](/genes/ncstn) — accessory subunits\n\n### Aβ Peptide Species\n\n| Species | Length | Aggregation | Toxicity | [@jack2018]\n|---------|--------|-------------|----------| [@palmqvist2024]\n| Aβ1-38 | 38 aa | Low | Minimal | [@jankord2024]\n| Aβ1-40 | 40 aa | Moderate | Moderate | [@oddo2003]\n| Aβ1-42 | 42 aa | High | High | [@van2023]\n| Aβ1-43 | 43 aa | Very high | Very high | [@sims2023]\n\nAβ42 and Aβ43 are more aggregation-prone and form the core of senile plaques [3].\n\n### Plaque Types\n\n1. **Diffuse plaques:** Non-fibrillar Aβ deposits, often in pre-clinical stages\n2. **Core plaques:** Dense-core Aβ with neuritic components\n3. **Plaques with dystrophic neurites:** Neuronal processes surrounding plaques\n4. **Cerebral amyloid angiopathy (CAA):** Aβ deposition in blood vessel walls [4]\n\n### Dystrophic Neurites\n\nDystrophic neurites are swollen, tortuous neuronal processes surrounding amyloid plaques:\n\n- Accumulate in response to local Aβ toxicity\n- Contain phosphorylated tau, ubiquitin, and other proteins\n- Represent early sign of neuronal injury\n- Correlate with local synaptic loss [5]\n\n## Tau Pathology\n\n### Tau Biology\n\n[Tau](/proteins/tau) is a microtubule-associated protein encoded by the [MAPT](/genes/mapt) gene:\n\n- Six isoforms (0N3R to 4N4R) via alternative splicing\n- Binds to and stabilizes microtubules\n- Primarily expressed in neurons\n- Regulates axonal transport and synaptic function [6]\n\n### Hyperphosphorylation\n\nIn AD, tau becomes abnormally phosphorylated at >45 sites:\n\n**Key phosphorylation sites:**\n- Ser202/Thr205 (AT8 epitope)\n- Thr212/Ser214 (AT100 epitope)\n- Ser396/Ser404 (PHF-1 epitope)\n- Thr181 (CSF biomarker)\n\nKinases involved:\n- [GSK-3β](/proteins/gsk-3-beta) — primary tau kinase\n- [CDK5](/genes/cdk5r1) — neuronal tau kinase\n- MAPK family members [7]\n\n### Neurofibrillary Tangles\n\nNFTs consist of paired helical filaments (PHFs) and straight filaments:\n\n1. **Pretangles:** Soluble hyperphosphorylated tau in cytoplasm\n2. **Intracellular NFTs:** Fibrillar tau in neuronal soma\n3. **Extracellular NFTs:** \"Ghost tangles\" after neuron death\n\nNFTs follow a predictable anatomical progression (Braak staging) [8]:\n\n| Stage | Regions Affected | Clinical Correlation |\n|-------|------------------|---------------------|\n| I-II | Transentorhinal | Preclinical |\n| III-IV | Limbic (hippocampus, amygdala) | MCI |\n| V-VI | Isocortical | Dementia |\n\n## Relationship Between Aβ and Tau\n\n### The Amyloid Cascade Hypothesis\n\nThe amyloid cascade hypothesis posits that Aβ accumulation is the primary trigger:\n\n1. Aβ accumulation → synaptic dysfunction\n2. Synaptic loss → tau hyperphosphorylation\n3. NFT formation → neuronal death\n4. Neurodegeneration → cognitive decline [9]\n\n### Evidence for Aβ-Tau Interaction\n\n**Supporting evidence:**\n- Aβ promotes tau pathology in animal models [10]\n- Tau facilitates Aβ toxicity [11]\n- Spatial correlation between plaques and NFTs\n- Genetic evidence (APP, PSEN1, PSEN2, APOE)\n\n**Challenging evidence:**\n- Plaque burden doesn't correlate with cognitive decline\n- NFT burden strongly correlates with cognitive status\n- Aβ-independent tauopathies exist\n- Many elderly have plaques without dementia\n\n### Updated Model: Multi-hit Hypothesis\n\nCurrent models suggest Aβ initiates a cascade, but multiple factors determine progression:\n\n- Aβ as an \"amplifier\" rather than sole cause\n- Tau spread via trans-synaptic mechanisms\n- Role of neuroinflammation, glial activation\n- Genetic modifiers (APOE, [TREM2](/genes/trem2)) [12]\n\n## Evidence Assessment\n\n### Confidence Level: Established\n\n| Evidence Type | Strength | Key Studies |\n|---------------|----------|-------------|\n| Histopathology | Strong | [1, 4, 8] |\n| Genetic Studies | Strong | [13, 14, 15] |\n| Biomarker Studies | Strong | [16, 17, 18] |\n| Animal Models | Strong | [19, 20] |\n| Clinical Trials | Moderate | [21, 22] |\n\n### Key Supporting Studies\n\n1. **Katzman (1988)** — Established Aβ plaques and NFTs as the defining lesions of AD [1]\n2. **Goate et al. (1991)** — First PSEN1 mutation linked to familial AD [13]\n3. **Strittmatter et al. (1993)** — APOE ε4 as major genetic risk factor [14]\n4. **Braak & Braak (1991)** — Systematic staging of NFT pathology [8]\n5. **Jack et al. (2018)** — AT(N) biomarker classification framework [17]\n\n### Testability Score: 10/10\n\n- Post-mortem histopathology definitively identifies both lesions\n- PET ligands detect plaques (Flutemetamol, Florbetapir) and tau (Flortaucipir) in vivo\n- CSF biomarkers measure Aβ42, total tau, and phosphorylated tau\n- Multiple therapeutic trials target Aβ and tau\n\n### Therapeutic Potential Score: 8/10\n\n- Three anti-Aβ antibodies now FDA-approved (Lecanemab, Donanemab, Aduhelm)\n- Active tau immunotherapy trials in progress\n- Earlier intervention correlates with better outcomes\n\n## Key Proteins and Genes\n\n| Protein/Gene | Role | Relevance |\n|--------------|------|-----------|\n| [APP](/genes/app) | Aβ precursor | Genetic cause of familial AD |\n| [PSEN1](/genes/psen1) | γ-secretase | Most common familial AD gene |\n| [PSEN2](/genes/psen2) | γ-secretase | Less common familial AD |\n| [APOE](/genes/apoe) | Lipid transport | Major genetic risk factor |\n| [TREM2](/genes/trem2) | Microglial receptor | Genetic risk factor (late onset) |\n| [MAPT](/genes/mapt) | Tau protein | Tau gene, risk for tauopathies |\n| [BIN1](/genes/bin1) | Bridging integrator | GWAS hit for sporadic AD |\n\n## Clinical Implications\n\n### Diagnostic Criteria\n\nThe NIA-AA research framework uses biomarker evidence:\n\n- **A+ (Amyloid positive):** PET or CSF evidence\n- **T+ (Tau positive):** PET or CSF evidence\n- **N+ (Neurodegeneration):** Atrophy, hypometabolism, or elevated t-tau\n\n\"AD\" is now defined by A+T+ status, regardless of clinical symptoms [17].\n\n### Biomarker Staging\n\n| Stage | Biomarkers | Clinical |\n|-------|-----------|----------|\n| Preclinical | A+ T- N- | Normal cognition |\n| MCI due to AD | A+ T+ N- | Mild impairment |\n| Dementia due to AD | A+ T+ N+ | Dementia |\n\n### Therapeutic Implications\n\n**Approved anti-amyloid therapies:**\n- **Lecanemab (Leqembi):** Aβ protofibril antibody, 27% slowing of decline [21]\n- **Donanemab (Kisunla):** N-terminal Aβ antibody, 35% slowing of decline [22]\n\n**In development:**\n- Tau immunotherapies (Semorinemab, Tilavonemab)\n- BACE inhibitors (stopped due to side effects)\n- Aggregation inhibitors\n\n## Related Hypotheses\n\n- [In Alzheimer's disease, biomarker events occur in a specific temporal sequence](/hypotheses/alzheimer's-disease,-biomarker-events-occur) — Aβ first, then tau, then neurodegeneration\n- [Amyloid plaque and neurofibrillary tangle deposition relationship](/hypotheses/amyloid-plaque-neurofibrillary-tangle-depositi) — mechanistic interaction\n- [Alterations in intra-regional functional connectivity](/hypotheses/hyp_146258) — Aβ and tau drive connectivity changes\n\n## See Also\n\n- [Alzheimer's Disease](/diseases/alzheimers-disease)\n- [Amyloid-Beta](/proteins/amyloid-beta)\n- [Tau Protein](/proteins/tau)\n- [Amyloid Plaques](/mechanisms/dopaminergic-neuron-vulnerability)\n- [Neurofibrillary Tangles](/mechanisms/neurofibrillary-tangles)\n- [Senile Plaques](/mechanisms/dopaminergic-neuron-vulnerability)\n- [APP](/genes/app)\n- [Presenilin 1](/mechanisms/dopaminergic-neuron-vulnerability)\n- [Presenilin 2](/mechanisms/dopaminergic-neuron-vulnerability)\n- [APOE](/genes/apoe)\n- [Mild Cognitive Impairment](/investment/mci)\n\n## External Links\n\n- [Alzheimer's Association](https://www.alz.org/)\n- [Alzheimer's Disease Neuroimaging Initiative (ADNI)](https://adni.loni.usc.edu/)\n- [SEA-AD Project](https://www.alzheimers.gov/alzheimers-dementias/alzheimers-disease-brain-cell-atlas-sea-ad)\n- [Allen Institute for Brain Science](https://portal.brain-map.org/)\n\n## References\n\n1. [Unknown, Katzman R. Alzheimer's disease. *N Engl J Med*. 1988;314(15):964-973 (1988)](https://doi.org/10.1056/NEJM198804143141509)\n2. [Unknown, Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. *Nat Rev Mol Cell Biol*. 2007;8(2):101-112 (2007)](https://doi.org/10.1038/nrm2101)\n3. [Unknown, Jarrett JT, Berger EP, Lansbury PT Jr. The C-terminus of the beta protein is critical in amyloidogenesis. *Ann Neurol*. 1993;33(4):423-428 (1993)](https://doi.org/10.1002/ana.410330418)\n4. [Unknown, Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K. Amyloid plaque core protein in Alzheimer disease and Down syndrome. *Proc Natl Acad Sci USA*. 1985;82(12):4245-4249 (1985)](https://doi.org/10.1073/pnas.82.12.4245)\n5. [Unknown, Dickson TC, Vickers JC. The morphological phenotype of beta-amyloid plaques and associated neuritic changes in Alzheimer's disease. *Neuroscience*. 2001;105(1):99-107 (2001)](https://doi.org/10.1016/S0306-4522(01)\n6. [Unknown, Mandelkow EM, Mandelkow E. Tau in physiology and pathology. *Nat Rev Neurosci*. 2014;15(1):25-39 (2014)](https://doi.org/10.1038/nrn3656)\n7. [Unknown, Hanger DP, Anderton BH, Noble W. Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. *Trends Mol Med*. 2009;15(3):112-119 (2009)](https://doi.org/10.1016/j.molmed.2009.01.003)\n8. [Unknown, Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol*. 1991;82(4):239-259 (1991)](https://doi.org/10.1007/BF00308809)\n9. [Unknown, Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. *Science*. 1992;256(5054):184-185 (1992)](https://doi.org/10.1126/science.1566067)\n10. [Unknown, Götz J, Ittner LM, Lim YA. Animal models of Alzheimer's disease and frontotemporal dementia. *Nat Rev Neurosci*. 2008;9(11):853-864 (2008)](https://doi.org/10.1038/nrn2470)\n11. [Unknown, Ittner LM, Götz J. Amyloid-beta and tau—a toxic pas de deux in Alzheimer's disease. *Nat Rev Neurosci*. 2011;12(2):65-72 (2011)](https://doi.org/10.1038/nrn2967)\n12. [Unknown, De Strooper B, Karran E. The cellular phase of Alzheimer's disease. *Cell*. 2016;164(4):603-615 (2016)](https://doi.org/10.1016/j.cell.2015.11.057)\n13. [Goate A, Chartier-Harlin MC, Mullan M, et al., Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature*. 1991;349(6311):704-706 (1991)](https://doi.org/10.1038/349704a0)\n14. [Strittmatter WJ, Saunders AM, Schmechel D, et al., Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset Alzheimer disease. *Proc Natl Acad Sci USA*. 1993;90(5):1977-1981 (1993)](https://doi.org/10.1073/pnas.90.5.1977)\n15. [Jonsson T, Atwal JK, Steinberg S, et al., A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. *Nature*. 2012;488(7409):96-99 (2012)](https://doi.org/10.1038/nature11283)\n16. [Unknown, Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: current status and future prospects. *Nat Rev Drug Discov*. 2018;17(5):297-312 (2018)](https://doi.org/10.1038/nrd.2018.2)\n17. [Jack CR Jr, Bennett DA, Blennow K, et al., NIA-AA research framework: toward a biological definition of Alzheimer's disease. *Alzheimer's Dement*. 2018;14(4):535-562 (2018)](https://doi.org/10.1016/j.jalz.2018.02.018)\n18. [Palmqvist S, van der Giessen L, Stomrud E, et al., Blood biomarkers to detect early-stage Alzheimer's disease. *JAMA Neurol*. 2024;81(3):231-241 (2024)](https://doi.org/10.1001/jamaneurol.2023.5281)\n19. [Unknown, Jankord R, Kofman P. Transgenic mouse models of Alzheimer's disease: mechanisms and therapeutic potential. *Nat Rev Drug Discov*. 2024;23(3):201-218 (2024)](https://doi.org/10.1038/s41573-024-00872-7)\n20. [Unknown, Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM. Amyloid deposition leads to synaptic deficits and cognitive decline in an Alzheimer's disease mouse model. *Neurobiol Aging*. 2003;24(7):997-1007 (2003)](https://doi.org/10.1016/j.neurobiolaging.2003.02.008)\n21. [van Dyck CH, Swanson CJ, Aisen P, et al., Lecanemab in early Alzheimer's disease. *N Engl J Med*. 2023;388(1):9-21 (2023)](https://doi.org/10.1056/NEJMoa2212948)\n22. [Sims JR, Zimmer JA, Evans CD, et al., Donanemab in early Alzheimer's disease. *N Engl J Med*. 2023;389(1):42-53 (2023)](https://doi.org/10.1056/NEJMoa2304840)",
  "entity_type": "hypothesis"
}